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Abstract 
The aims of this Thesis was to evaluate the role of proangiogenic placental growth factor (PlGF), 
antiangiogenic endostatin and lymphangiogenic vascular endothelial growth factor (VEGF) -C as 
well as the receptors vascular endothelial growth factor receptor (VEGFR) -2 and VEGFR-3 
during lung development and in development of lung injury in preterm infants. The studied 
growth factors were selected due to a close relationship with VEGF-A; a proangiogenic growth 
factor important in normal lung angiogenesis and lung injury in preterm infants. 
The thesis study consists of three analyses. I: Lung samples from fetuses, preterm and 
term infants without lung injury, as well as preterm infants with acute and chronic lung injury 
were stained by immunohistochemistry for PlGF, endostatin, VEGF-C, VEGFR-2 and 
VEGFR-3. II: Tracheal aspirate fluid (TAF) was collected in the early postnatal period from a 
patient population consisting of 59 preterm infants, half developing bronchopulmonary 
dysplasia (BPD) and half without BPD. PlGF, endostatin and VEGF-C concentrations were 
measured by commercial enzyme-linked immunosorbent assay (ELISA). III: Cord plasma was 
collected from very low birth weight (VLBW) (n=92) and term (n=48) infants in conjuncture 
with birth and endostatin concentrations were measured by ELISA. 
I: All growth factors and receptors studied were consistently stained in 
immunohistochemistry throughout development. For endostatin in early respiratory distress 
syndrome (RDS), no alveolar epithelial or macrophage staining was seen, whereas in late 
RDS and BPD groups, both alveolar epithelium and macrophages stained positively in 
approximately half of the samples. VEGFR-2 staining was fairly consistent, except for the 
fact that capillary endothelial staining in the BPD group was significantly decreased. 
II: During the first postnatal week in TAF mean PlGF concentrations were stable 
whereas mean endostatin and VEGF-C concentrations decreased. Higher concentrations of 
endostatin and VEGF-C correlated with lower birth weight (BW) and associated with 
administration of antenatal betamethasone. Parameters reflecting prenatal lung 
inflammation associated with lower PlGF, endostatin and VEGF-C concentrations. A 
higher mean supplemental fraction of inspired oxygen during the first 2 postnatal weeks 
(FiO2) correlated with higher endostatin concentrations. 
III: Endostatin concentrations in term infants were significantly higher than in VLBW 
infants. In VLBW infants higher endostatin concentrations associated with the development 
of BPD, this association remained significant after logistic regression analysis. 
We conclude that PlGF, endostatin and VEGF-C all have a physiological role in the 
developing lung. Also, the VEGFR-2 expression profile seems to reflect the ongoing 
differentiation of endothelia during development. Both endostatin and VEGFR-2 seem to 
be important in the development of BPD. During the latter part of the first postnatal week, 
preterm infants developing BPD have lower concentrations of VEGF-A in TAF. Our 
findings of disrupted VEGFR-2 staining in capillary and septal endothelium seen in the 
BPD group, as well as the increase in endostatin concentrations both in TAF and cord 
plasma associated with BPD, seem to strengthen the notion that there is a shift in the 
angiogenic balance towards a more antiangiogenic environment in BPD. These findings 
support the vascular hypothesis of BPD. 
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Introduction 
Advances in neonatology during the latter part of the 20th century and the first decade of 
the 21st century have led to a decreasing mortality rate among ever-smaller preterm infants. 
Currently mortality rates for infants born at a gestational age (GA) of 22 weeks are 
reported to be about 95%, at 24 weeks 60% and at 26 weeks 25% (Moser et al, 2008). Due 
to an increase in the overall preterm delivery rate (Goldenberg et al, 2008) and the 
decreased mortality rate, there are more preterm infants surviving than ever before. Thus, 
despite advances in treatment, morbidity remains high and remains a significant challenge 
when treating preterm infants. 
Since the 1940s, preterm infants have been able to survive due to the use of 
supplemental oxygen and mechanical ventilation. In the early days ventilation strategies 
had to be aggressive to achieve appropriate oxygenation and ensure survival of the infant. 
The aggressive treatment led to the development chronic lung disease, BPD first described 
in 1967 (Northway et al, 1967). The disorder was characterized by inflammation, fibrosis 
and smooth muscle hypertrophy in the airways.  
Ever since BPD was first described in 1967, knowledge about the disorder and 
appropriate treatment strategies have been strenuously studied. Advances in mechanical 
ventilation, better methods for administration of supplemental oxygen, the introduction of 
surfactant and antenatal glucocorticoid therapy have changed the whole survival profile of 
preterm infants from that seen in the 1970s. It has also led to a temporal shift in BPD from 
infants with GA of around 34-37 weeks, to infants with GA below 32 weeks. Subsequently 
the whole pathogenesis of BPD has changed. Currently less inflammation and fibrosis of 
the airways is seen. Instead autopsy findings in infants with fatal BPD reveal a persistence 
of simple terminal air spaces, consistent lack of significant alveolarization and dysmorphic 
pattern of vascular organization which all in all leads to emphysematous appearing lungs 
(Husain et al, 1998; Bhatt et al, 2001). As highlighted by these autopsy findings, birth at 
the early part of the third trimester interrupts the normal development of the lung and the 
development of BPD is believed to be due to a disruption of vascular development in 
preterm infants (Jobe, 1999; Abman, 2001; Zoban & Cerny, 2003; Abman, 2008). 
Previously, VEGF-A has been shown to play an important part in normal angiogenesis 
in addition as having a role in the development of BPD (Lassus et al, 1999). We chose to 
study growth factors and receptors associated with VEGF-A in order to increase our 
understanding of normal lung angiogenesis as well as the development of BPD. 
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Review of the literature 
1. Normal development of the human lung 
1.1 Development of the lung  
Traditionally, lung development is divided into five distinct but overlapping stages based 
on the histologic appearance of the developing epithelium (Figure 1). The basis of lung 
formation through various biologic processes and genetic pathways is laid down during 
gastrulation at around a GA of 5 weeks when the embryo forms three specific germ layers. 
One of these germ layers, the endoderm, organizes and forms the gut tube out of which 
several organ domains then bud (reviewed in Haddad et al, 2002). Genetic transcription 
during lung development has been studied intensely during the last decade. The complexity 
surrounding the regulation of transcription is evident from the various cell types that exist 
in the lung, ectodermal, mesenchymal and endodermal, all in appropriate numbers and 
locations to ultimately enable respiration. 
 
Figure 1. The various stages of lung development with respect to gestational age/postnatal months. In the 
schematic drawing of microvascular maturation the oval circles depict endothelial cells and the rectangular 
forms connective tissue. Microvascular maturation proceeds from a double-capillary layer sandwiching 
connective tissue (a) to a single capillary layer with connective tissue intertwined (b). 
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1.1.1 Embryonic stage (GA 3 to 7 weeks) 
The human lung buds out of the gut tube during the embryonic stage of lung development. 
On gestational day 26, lung and trachea can be recognized as a ventral outpouching of the 
foregut. This structure consists of the future trachea and two primordial lung buds. The 
lung buds then initiate branching morphogenesis. By the fifth week, outgrowth, elongation 
and branching of the two primordial bronchial lung buds create five bronchial stems, three 
on the right and two on the left. These stems are the foundation for the future lung lobes of 
the mature lung.  
1.1.2 Pseudoglandular stage (GA 5 to 17 weeks) 
The pseudoglandular stage is characterized by continuation of branching morphogenesis of 
the pulmonary tree until the pre-acinary level. At the end of this developmental stage at 
around a GA of 17 weeks, the lung has completed its branching morphogenesis and 
bronchopulmonary segments have been formed. At this stage, all the airway divisions down 
to the level of alveolar ducts are present (Kitaoka et al, 1996). Branching morphogenesis can 
be considered to create the backbone of the lung with an extensive three-dimensional network 
of bronchi and bronchioles. It transforms the primordial buds consisting of undifferentiated 
epithelial cells surrounded by mesenchyme into a highly organized tree-like organ. This is the 
basis for the extensive gas-exchanging unit that is the mature human lung. The process 
requires dynamic and reciprocal interactions between the epithelium and the surrounding 
mesenchyme. On a cellular level, fibroblast growth factor-10, bone morphogenic protein 4, 
sonic hedgehog and transforming growth factor-β (TGF- β) all play important roles in this 
process. Simplified, branching morphogenesis consists of bud outgrowth followed by an 
elongation of the bud and finally subdivision of the terminal portion of the bud to form new 
buds and continue the branching process (Weaver et al, 2000). 
1.1.3 Canalicular stage (GA 16 to 26 weeks)  
The canalicular stage of development initiates the formation of structures that are capable 
of gas-exchange in the lung. First, terminal bronchioles divide to form two respiratory 
bronchioles. The respiratory bronchioles then branch into 3 to 6 primitive alveolar ducts, 
which end in terminal sacs. This completes the formation of the prospective gas-
exchanging tissue, the acinus. At this stage, the acinary structure is immature but contains 
the cells needed for respiration. Within the acinus bronchiolar cells start to differentiate, 
initially to become type II pneumocytes. The type I pneumocyte may then develop from a 
type II pneumocyte, if the type II pneumocyte is situated in close proximity to a capillary 
artery. Importantly, capillary arteries begin to proliferate and come into closer contact with 
epithelial cells; canalizing the lung parenchyma.  
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1.1.4 Saccular stage (GA 24 weeks to term) 
During the saccular stage, the terminal sacs dilate and branch to form further generations of 
terminal sacs, finally forming transitory ducts and transitory saccules. The walls of the 
saccules are still immature and contain a central layer of connective tissue surrounded by a 
double capillary network. This immature wall of the saccule is known as the primary 
septum. This is considered the basis from which mature lung-exchanging structures bud 
during alveolarization. Type-I cells continue to flatten and spread, increasing the surface 
area available for gas exchange. 
1.1.5 Alveolar stage (GA 28 weeks to 1-2 years postnatally) 
The alveolar stage, alveolarization, can be divided into two separate, yet overlapping 
processes; septation and microvascular maturation. Alveolarization represents a very 
important developmental step in evolution, increasing the lung gas exchanging surface area 
of humans about 20-fold between birth and adulthood.  
The process of alveolarization begins relatively late in gestation and continues for 1-
2 years postnatally. The phenomenon of alveolarization is currently under scrutiny as late 
secondary alveolar growth after the process of microvascular maturation, so called late 
alveolarization, is being suggested as a significant contributor to overall alveolarization 
(Burri, 2006; Mund et al, 2008; Schittny et al, 2008). 
1.1.6 Alveolarization 
Septation initiates alveolarization. A secondary crest, containing a connective tissue layer 
surrounded by a double capillary layer, starts to grow into the airspace from the primary 
septum, dividing the saccule into what are now termed alveoli. Septation involves 
coordinated outgrowth of epithelial cells, a capillary network and alveolar myofibroblasts 
at the alveolar septal tips. The sheet of connective tissue in the middle of the septum is in 
part made of elastic fibers. Elastic fiber formation in the lung peaks as septation of the 
distal air spaces occurs (Mariani et al, 2002), suggesting that the elastic matrix is critical in 
this process.  
There is a critical timeframe for septation and any interruption of septation could 
lead to hypoplasticity and a decreased gas-exchanging area. In rats, treatment with 
dexamethasone at the time of septation prevented septation, withdrawal of dexamethasone 
treatment did not lead to spontaneous re-establishment of septation (Massaro & Massaro, 
1992; Blanco & Frank, 1993).   
After septation, the second part of alveolarization, microvascular maturation, 
commences. Ultmately it transforms alveolar septa from having a double-capillary layer 
separated by connective tissue, into septa with a single capillary layer that contains 
intertwining connective tissue. This encompasses thinning of alveolar septa of distal 
airspaces by epithelial cell flattening and apoptosis (Massaro & Massaro, 1996). It is 
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difficult to assess exactly when microvascular maturation begins and when it is complete. 
Ultrastructural and morphometric studies in the rat show that the merging of the two 
capillary layers is initiated by a decrease of the dividing septal connective tissue. The two 
capillary layers merge their lumina after coming into a close contact with each other. The 
process of preferential growth then expands capillary structures, further increasing the 
surface area for gas exchange (Burri, 2006).  
As mentioned earlier, the issue of late alveolarization has been raised. Subpleural 
areas of the lung represent sites suited for the addition of new alveoli even during 
adulthood. On careful examination of the adult lung, disseminated septa with an immature 
aspect, i.e. a double capillary layer surrounding connective tissue, can be found (Burri, 
2006). Whether the capacity for late alveolarization can significantly increse gas-exchange 
capacity in preterm infants who have developed BPD is unknown. This issue is perhaps of 
greater interest in recovery from adult lung insult than it is in the pathogenesis of BPD and 
the aspect of this Thesis. 
1.2 Vascular development in the human lung 
The pulmonary artery and pulmonary veins are established at the end of the embryonic 
stage of lung development. However, it is during the next stage of development, the 
pseudoglandular stage, that vascular development of the lung truly accelerates. At the same 
time that branching morphognesis forms the basis of epithelial structures, vascular 
development lays down the foundation for endothelial structures critical in later 
development of the gas-exchanging parenchyma of the lung.  
The lung vasculature develops through both angiogenesis, in which vessels are 
formed from pre-existing vessels, as well as by vasculogenesis, in which blood lakes 
appear de novo. Initially these two systems are separated; on day 50.5 (GA of 7 weeks) 
five to six generations of airway branches have formed and blood-lakes are in abundance 
in the subpleural mesenchyme. However, by this stage the pulmonary artery has only 
reached the third or fourth generation of airway branches. On day 54, many weeks before a 
connection between the developing pulmonary artery and the capillary network is formed, 
a hilar vein is seen connecting to the peripheral lakes, establishing venous drainage. 
Between a GA of 12-16 weeks, the peripheral blood-lakes have established an extensive 
network of capillaries surrounding the most peripheral lung buds (deMello & Reid, 2000). 
By the GA of 22-23 weeks, the capillary network approaches and bulges into the 
airspace. Additionally, at this stage the pulmonary artery accompanies even the most distal 
airway branch under the pleura. It seems that fusion between angiogenesis and 
vasculogenesis occurs during this, the canalicular, stage of development (deMello & Reid, 
2000). The capillary network then continues to expand and becomes more complex. The 
development of lung vasculature ends with microvascular maturation described in the 
section on alveolarization above. 
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1.3 Lymphatic development in the human lung 
The lymphatic vasculature is important for the collection of protein-rich exudate leaking from 
blood vessels, as well as for playing a part in the body’s immune response. The lymphatic 
system is an open-ended linear system through which tissue fluid (lymph) is drained from the 
interstitial space of most organs. The lymph is then transported from thin initial capillaries to 
the larger collecting lymphatics that are eventually connected by means of the thoracic duct to 
the inferior vena cava for recirculation (reviewed in Hong et al, 2004). 
The development of the lymphatic system is relatively poorly understood. In 1902, 
Floorence Sabin proposed that lymphatic sacs bud out of veins during embryogenesis and 
that the lymphatic vasculature proceeds to grow from this early basis (Sabin, 1902). This 
theory has recently been proved to be correct by studies on mice. In these studies, the 
prospero-related homeobox 1 (Prox1) gene was required for a subset of venous endothelial 
cells (ECs) in the embryonic cardinal veins to migrate out, to form the initial lymphatic 
vessels during early embryogenesis (Wigle & Oliver, 1999; Wigle et al, 2002). These 
budding lymphatic ECs eventually gave rise to the primary lymph sacs, from which 
lymphatic vessels then spread to peripheral tissues of the embryo (Wigle & Oliver, 1999). 
It is believed that all venular ECs may originally be bipotent, being able to differentiate 
towards becoming either venous or lymphatic ECs. But when these cells simultaneously 
express lymphatic vessel endothelial HA receptor-1 (LYVE-1), Prox1, VEGFR-3 and 
secondary lymphoid chemokine, they lose their bipotency and become irreversibly 
commited to the lymphatic EC lineage (Wigle et al, 2002). 
2. Proangiogenic growth factors in the preterm lung 
2.1 Overview of proangiogenic growth factors 
Angiogenesis in the human lung involves intricate and complex regulation by a wide 
variety of factors. The role of transcriptional factors and genes and other proangiogenic 
molecules are immensely important for vascular development but are not within the scope 
of this Thesis. Instead, we shall focus our attention on growth factor-receptor pairs. While 
the VEGF-A-VEGFR system is regarded as the most important during vascular 
development, the angiopoietin and ephrin systems in addition to platelet-derived growth 
factor are all recognized as important in lung development. 
Ephrin receptors are divided into Ephrin A and Ephrin B kinases according to 
sequence homology and binding specificity to membrane bound ephrin ligands (Miao & 
Wang, 2008). In total, the ephrin family consists of 14 known receptors and at least 8 ligands 
and it functions in the growth and development of the neuronal and vascular systems 
(O'Leary & Wilkinson, 1999; Adams & Klein, 2000; Pasquale, 2005). Of the ligands, 
ephrinA1 has been shown to have angiogenic properties (Pandey et al, 1995; Daniel et al, 
1996) and recently to increase EC permeability (Larson et al, 2008) and ephrinB2 acts as an 
arterial cell marker during early embryonic development (Wang et al, 1998). 
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Platelet derived growth factor is an important regulator of angiogenesis by acting to 
increase proliferation and survival of smooth muscle cells and pericytes (Claesson-Welsh, 
1994). In addition, platelet derived growth factor has been shown to induce direct EC 
growth (Shibuya, 2008). 
2.2 Vascular endothelial growth factor-A (VEGF-A) 
2.2.1 Background 
VEGF-A was the first member of the VEGF family to be identified (Figure 2). The family 
also includes VEGF-C, VEGF-D and PlGF discussed later, as well as less studied growth 
factors VEGF-B (Nash et al, 2006), VEGF-E (Meyer et al, 1999) and VEGF-F (Suto et al, 
2005). VEGF-A was discovered in 1983 by Senger and coworkers as a vascular permeability 
factor secreted by tumor cells (Senger et al, 1983). It was found to be a potent EC mitogen 
capable of regulating physiological and pathological angiogenesis, and in 1989, it was 
termed VEGF (Ferrara & Henzel, 1989; Leung et al, 1989; Plouet et al, 1989).  
The human VEGF-A gene is located on chromosome 6p21.3 (Vincenti et al, 1996). 
Alternative exon splicing of a single VEGF gene results in six isoforms of VEGF-A. Four 
mature isoforms; VEGF121, VEGF165, VEGF189 and VEGF206, as well as two less 
commonly expressed isoforms; VEGF145 and VEGF183 (Houck et al, 1991; Tischer et al, 
1991; Shima et al, 1996; Poltorak et al, 1997; Jingjing et al, 1999). VEGF165 is the 
predominant molecular species produced by the cells (Houck et al, 1991). VEGF165, 
VEGF189 and VEGF206 all bind to heparin. Loss of this heparin biding ability results in a 
reduction of mitogenic activity of vascular ECs (Keyt et al, 1996). 
2.2.2 Biological activity of VEGF-A 
VEGF-A exerts its biologic effect through interaction with cell-surface receptors. These 
receptors are transmembrane tyrosine kinase receptors VEGFR-1 (fms-like tyrosine kinase-
1) as well as VEGFR-2 (fetal liver kinase-1/kinase insert domain receptor), selectively 
expressed on vascular ECs to which VEGF-A binds with high affinity (Veikkola et al, 2000). 
VEGFR-1 and VEGFR-2 are discussed in more detail below. 
VEGF-A is the most potent proangiogenic protein described to date. It induces 
proliferation, sprouting and tube formation of ECs (Ferrara et al, 2003). It is also a potent 
survival factor for ECs, and has been shown to induce the expression of antiapoptotic 
proteins in these cells (Benjamin & Keshet, 1997; Gerber et al, 1998). 
VEGF-A is regulated by several separate factors and pathways. Oxygen tension is a 
key regulator of VEGF-A gene expression (Shweiki et al, 1992). Low pO2 rapidly and 
reversibly induces VEGF-A expression through hypoxia inducible factor-α (Liu et al, 
1995). A number of cytokines, hormones and growth factors are able to up-regulate VEGF-
A messenger ribonucleic acid (mRNA) expression in various cell-types. In addition, 
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VEGF-A seems to have a role in inflammation, as suggested by the up-regulation of 
VEGF-A expression by inflammatory mediators (Ben-Av et al, 1995; Horiuchi & Weller, 
1997; Nauck et al, 1997). 
 
Figure 2. VEGF family of growth factors and receptors. R1 denotes VEGFR-1, R2 VEGFR-2 and R3 VEGFR-
3. Modified and reproduced here with permission from the copyright holder (Ferrara et al, Nat Med 9: 669-
676; 2003). 
2.2.3 VEGF-A in physiological angiogenesis 
In human fetuses VEGF-A mRNA can be detected in all tissues, most abundantly in lung, 
kidney and spleen. VEGF-A is localized in epithelial cells and myocytes, including smooth 
muscle cells lining blood vessel walls (Shifren et al, 1994; Acarregui et al, 1999). High 
levels of VEGF-A mRNA (Kaipainen et al, 1993) and protein (Shifren et al, 1994) have 
also been localized in airway epithelial cells in human fetal lung during the second 
trimester. Increased VEGF-A gene expression in distal airway epithelial cells has been 
shown to associate with the spontaneous differentiation of human fetal lung in vitro, and 
VEGF-A seems to direct the development of the alveolar capillary bed (Acarregui et al, 
1999). Inactivation even of a single VEGF-A allele in mice results in early embryonic 
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lethality. VEGF-A-/+ embryos are growth retarded and exhibit a number of developmental 
anomalies; formation of blood vessels is abnormal in heterozygous VEGF-A deficient 
embryos, and is even more impaired in homozygous VEGF-A deficient embryos 
(Carmeliet et al, 1996; Ferrara et al, 1996).  
2.3 Placental growth factor (PlGF) 
2.3.1 Background 
Human PlGF was initially located in the human placenta (Maglione et al, 1991), but has 
since been located also in the heart and lung. PlGF binds mainly to VEGFR-1 (Yla-
Herttuala & Alitalo, 2003). The proangiogenic action of PlGF is mediated indirectly 
through VEGFR-2. VEGFR-2 is a receptor tyrosine kinase (Terman et al, 1991), which 
binds VEGF-A, VEGF-C, and VEGF-D, and is recognized as the primary receptor 
transmitting signals in ECs (Wise et al, 1999; Zachary & Gliki, 2001). Since VEGF-A 
binds to both VEGFR-1 and VEGFR-2, it is suggested that PlGF boosts angiogenesis by 
binding to VEGFR-1, thus decreasing the amount of free VEGFR-1. A larger percentage of 
VEGF-A instead binds to VEGFR-2 (Park et al, 1994). In addition, PlGF seems to have a 
distinct unique angiogenic signalling pathway through VEGFR-1 (Cao et al, 1996; Neufeld 
et al, 1999; Shibuya et al, 1999) (Figure 3). 
 
Figure 3. The binding pattern of VEGF-A and PlGF during angiogenesis. a) During physiological angiogenesis 
VEGF-A binds equally to VEGFR-1, VEGFR-2 and sVEGFR-1. b) In pathological angiogenesis PlGF binding 
to VEGFR-1 allows an increased number of VEGF-A molecules to bind to VEGFR-2. In addition, PlGF may 
stimulate angiogenesis directly by binding to VEGFR-1, as well as by forming a heterodimer pair with VEGF-A, 
inducing the formation of VEGFR-1/VEGFR-2 receptor heterodimers. Modified and reproduced here with 
permissionfrom the copyright holder (Tjwa et al, Cell Tissue Res 2003;314:5-14). 
2.3.2 PlGF in physiological development 
PlGF knockout mice do not exhibit any abnormalities in developmental angiogenesis or 
vasculogenesis, however, these mice suffer from impaired angiogenesis in states of 
ischemia such as myocardial infarction, inflammation, wound healing and tumor growth 
(Carmeliet et al, 2001).  
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2.4 Vascular endothelial growth factor receptors 1&2 (VEGFR-1 and VEGFR-2) 
Both VEGFR-1 and VEGFR-2 have seven immunoglobulin-like domains in the 
extracellular domain, a single transmembrane region and a tyrosine kinase domain 
(Terman et al, 1991; de Vries et al, 1992). VEGFR-1 was the first receptor tyrosine kinase 
to be recognized as a VEGF family receptor in 1992 (de Vries et al, 1992). VEGFR-1 
expression is upregulated by a hypoxia inducible factor-α dependent mechanism (Gerber et 
al, 1997). In addition to VEGF-A, VEGFR-1 also binds to PlGF (Park et al, 1994) and 
VEGF-B (Olofsson et al, 1998), both of which do not bind to VEGFR-2. VEGFR-1 
undergoes only weak tyrosine autophosphorylation in response to VEGF-A binding (de 
Vries et al, 1992; Waltenberger et al, 1994). This finding seems to indicate that VEGFR-1 
acts as a “decoy” receptor by binding VEGF-A, thus preventing VEGF-A from binding to 
its major signal transducing receptor, VEGFR-2 (Park et al, 1994). This decoy effect can 
also be performed by the soluble form of the receptor, s-VEGFR-1 (Carmeliet et al, 2001). 
The importance of VEGFR-1 in early fetal development is illustrated by lethality of 
VEGFR-1-null mice, which die in utero between embryonic day 8.5 and 9.5 (Fong et al, 
1995; Fong et al, 1999). These mice exhibit an excessive proliferation of angioblasts and 
failure of ECs to organize into channels (Fong et al, 1999). 
VEGFR-2 is the major mediator of the mitogenic, angiogenic and permeability-
enhancing effects of VEGF-A. The importance of VEGFR-2 in vascular development is 
highlighted by the fact that VEGFR-2-null mice fail to develop blood-islands and vessels 
altogether, dying in utero between embryonic day 8.5 and 9.5 (Shalaby et al, 1995). However, 
at least in vitro, endothelial/hematopoietic precursor cells can be derived from VEGFR-2-
deficient embryonic stem cells, demonstrating that VEGFR-2 is not required for the formation 
of the common hematopoietic/endothelial progenitor cell, the so-called hemangioblast 
(Hidaka et al, 1999; Schuh et al, 1999). VEGFR-2 thus seems to be critical in EC 
commitment as well as VEGF-A directed hemangioblast migration to suited environments in 
the developing embryo (Shalaby et al, 1997; Hidaka et al, 1999; Schuh et al, 1999). In 
addition, VEGFR-2 has previously been detected on lymphatic ECs (Makinen et al, 2001a). 
In summary, VEGF-A binds VEGFR-2 and forms the developing vasculature which, 
at least in early development, is shaped and directed by the activity of VEGFR-1. 
2.5 Angiopoietin 1 
Angiopoietin 1 is expressed by many different cell types, and angiopoietin 1 mRNA 
expression has been detected early in fetal development in myocardium, followed by 
expression in mesenchyme surrounding blood vessels (Davis et al, 1996). In transgenic 
mice, angiopoietin 1 induces more abundant, more highly branched and larger blood 
vessels than in wild type mice (Suri et al, 1998). The phenotypes of angiopoietin 1 and 
tyrosine kinase with Ig and EGF homology domains (Tie) -2, the receptor of all 
angiopoietins including angiopoietin 1, deficient mice suggest a role for this ligand-
receptor system in maintaining the communication between ECs and the surrounding 
mesenchyme. This communication is critical in order to establish stabilization of the 
formed blood vessel wall, and is established by cellular and biochemical interactions 
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between ECs and mesenchyme (Dumont et al, 1994; Puri et al, 1995; Suri et al, 1998; 
Thurston et al, 1999). The importance of this stabilization is highlighted by the fact that 
VEGF-A gene treatment alone leads to improved vessel generation, but the vessels are 
immature and leaky (Kunig et al, 2005b; Thebaud et al, 2005; Kunig et al, 2006b). 
Combined VEGF-A and angiopoietin 1 gene transfer preserves alveolarization, and 
enhances angiogenesis with more mature blood vessels that are less permeable, reducing 
the vascular leakage seen in VEGF-A-induced vessels (Thebaud et al, 2005). 
2.6 Tyrosine kinase with Ig and EGF homology domains (Tie) receptors 
There are two members of the Tie class of receptor tyrosine kinases, Tie-1 and Tie-2. Both 
receptors are predominantly expressed by vascular ECs (Loughna & Sato, 2001). Whereas 
all the angiopoietins bind Tie-2, Tie-1 has no known ligands to date (Davis et al, 1996; 
Maisonpierre et al, 1997; Valenzuela et al, 1999). Tie-2 activation triggers several 
signalling pathways with downstream targets leading to an antiapoptotic, anti-
inflammatory, antipermeable, prosprouting effect on ECs (Eklund & Olsen, 2006). Tie-2-/- 
mice die between embryonic day 9.5 and 10.5 due to lack of remodelling of the primary 
capillary plexus. The development of the heart also shows severe defects with poor 
associations between ECs and the underlying extracellular matrix (Dumont et al, 1994; 
Sato et al, 1995). There is an absolute requirement for Tie-2 in endocardium on embryonic 
day 10.5, otherwise both Tie-1 and Tie-2 are initially, at least partly, dispensable for the 
development of the rest of the vasculature (Puri et al, 1999). However, both play a role 
during late organogenesis in the development of the microvasculature as well as in 
virtually all adult blood vessels and postnatal bone marrow hematopoiesis (Puri & 
Bernstein, 2003). 
The function of Tie-1 has been elusive, mostly because a binding ligand has been 
difficult to identify. Tie-1 is unphosphorylated, and it does not induce tyrosine 
phosphorylation of cellular proteins in ECs, indicating that Tie-1 does not act via ligand-
induced kinase activity (McCarthy et al, 1999; Marron et al, 2000b). However, a soluble 
angiopoietin 1 chimeric protein, COMP-angiopoietin 1, has recently been shown to induce 
phosphorylation of Tie-1. This effect was strengthened by the ability of Tie-1 to forms 
heterodimeric complexes with Tie-2 (Saharinen et al, 2005). Heterodimerization could be a 
way in which Tie-1 might modulate both its own, and Tie-2, signalling in a ligand 
independent fashion (Marron et al, 2000a; Marron et al, 2000b; Tsiamis et al, 2002; 
Saharinen et al, 2005). Before these mechanisms of Tie-1 action were discovered, in vivo 
studies illustrated a role for Tie-1 in vascular development; EC survival and extension of 
the vascular network during late embryogenesis, particularly regions of capillary 
angiogenic growth, required Tie-1 activation. Mice lacking Tie-1 die between embryonic 
day 13.5 and the immediate postnatal period due to severe hemorrhage and edema (Puri et 
al, 1995; Sato et al, 1995). 
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3. Antiangiogenic growth factors in the preterm lung  
3.1 Overview of antiangiogenic growth factors 
In contrast to proangiogenic growth factors, much less is known about the function of 
antiangiogenic growth factors in the development of lung vasculature and about their potential 
role in lung injury of preterm infants. Most known antiangiogenic growth factors have been 
discovered in conjuncture with cancer research as potential targets for tumor therapy.  
Angiostatin (Holmgren et al, 1995; Ruegg et al, 2006), pigment epithelium-derived 
factor (Dawson et al, 1999; Zhang et al, 2005) and maspin (Zou et al, 1994; Zhang et al, 
2000; Solomon et al, 2006) are all recognized as regulators of pathologic angiogenesis, 
particularly tumor angiogenesis. In addition, pigment epithelium-derived factor has been 
shown to be downregulated during pathologic neovascularization of the retina (Gao et al, 
2001) and in pulmonary fibrosis (Cosgrove et al, 2004). In developing mice, lack of 
pigment epithelium-derived factor results in increased stromal vasculature and epithelial 
cell hyperplasia both in the prostate and kidney (Doll et al, 2003). The role of these growth 
factors in the developing human lung is unknown. 
Endothelial monocyte-activating polypeptide-II (EMAP-II) also acts in an 
antiangiogenic fashion. EMAP-II is known to be expressed in the mouse lung in utero,  and 
decreasing levels of EMAP-II coincide with rapid vascularization. Postnatally, 
concentrations in the lung remain low except for the period of microvascular maturation 
(Schwarz et al, 1999b). Increased levels of EMAP-II have also been associated with 
decreased vasscularization and development of BPD in preterm baboons (Quintos-
Alagheband et al, 2004). 
3.2 Endostatin 
3.2.1 Background 
Endostatin is a 20 kDa proteolytic fragment of the C-terminal nontriple-helical domain of 
collagen XVIII (O'Reilly et al, 1997). It was discovered in cancer research and is the first 
endogenous inhibitor of angiogenesis to be identified in a matrix protein (Folkman, 2006). 
Endostatin has been identified as a component in nearly all endothelial and epithelial 
basement membranes (Muragaki et al, 1995; Fukai et al, 2002). Early experimentation 
utilized endostatin from tumor bearing mice. Endostatin was then produced in Escheria 
coli (O'Reilly et al, 1997). Experimentation in mice showed a dramatic inhibitory effect on 
tumors when soluble endostatin was administered subcutaneously (Boehm et al, 1997). 
These results were difficult to duplicate and many remained sceptical towards the 
antitumor effects of endostatin. These problems were overcome with the production of 
soluble endostatin in yeast (Pichia pastoria) (Folkman, 2006). Problematically, the effect 
of bolus administration of the soluble form of endostatin on tumors was not as great as that 
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of the insoluble form. This problem could be overcome by administering soluble endostatin 
continuously. This proved to be just as efficient as administration of the insoluble form 
(Capillo et al, 2003). This suggests that endostatin has a short half-life and circulating 
concentrations need to be elevated in order for endostatin to achieve maximum efficiency 
in tumor inhibition.  
The inhibitory effect of endostatin on ECs includes inhibition of proliferation 
(O'Reilly et al, 1997), migration (Dhanabal et al, 1999; Yamaguchi et al, 1999) and 
induction of cell apoptosis (Dhanabal et al, 1999; Dixelius et al, 2000).  
3.2.2 Antiangiogenic action of endostatin 
Endostatin’s mechanism of action has been described as broad-spectrum antiangiogenic. 
Abdollahi and coworkers showed, using custom microarrays covering over 90% of the 
human genome that 12% of all genes were significantly regulated in human microvascular 
ECs exposed to endostatin. Angiogenesis inhibitors were upregulated, while angiogenesis 
stimulators were downregulated (Abdollahi et al, 2004). 
Since the discovery in 1997, numerous studies have shown that the physiological 
actions of endostatin are diverse and broad. Endostatin levels are elevated in certain types 
of cancer, in intratumoral fluid and malignant ascites (van Hensbergen et al, 2002), as well 
as in chronic inflammatory diseases such as rheumatoid arthritis (Hebbar et al, 2000) and 
diabetic retinopathy (Funatsu et al, 2001). As mentioned above, endostatin has also been 
shown to inhibit growth and proliferation of certain tumours (Ramchandran et al, 2002).  
3.2.3 Endostatin in physiological development 
Several studies have implicated, that while endostatin may be a factor in physiological 
angiogenesis, it is not a critical one. The impact of endostatin on physiological 
angiogenesis has been studied in a mouse model (Li & Olsen, 2004). Apart from ocular 
abnormalities, endostatin knockout mice exhibited no major vascular abnormalities. 
However, aortic explants from these mice showed a twofold increase in the number and 
length of microvessels, suggesting a more proangiogenic environment. Endostatin 
modulates cell-matrix interactions locally and acts as an antiangiogenic regulator. This 
action destabilizes vessel walls and can lead to vessel regression (Li & Olsen, 2004). 
Endostatin is critical for human retinal development and normal blood vessel formation in 
the eye (Sertie et al, 2000; Fukai et al, 2002); it seems to affect EC migration and guidance 
in the developing retina. Col18a1-/- mice exhibited abnormal bending of major retinal blood 
vessels, but no perfusion deficits or vascular leakage were observed (Marneros & Olsen, 
2003). Thus, the abnormal retinal vasculature in these mutant mice did not seem to affect 
retinal function or morphology (Marneros et al, 2004). 
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3.3 Angiopoietin 2 
Angiopoietin 2 is a protein containing 496 amino acids (Maisonpierre et al, 1997), and 
expression of angiopoietin 2 has been detected at sites of active angiogenesis 
(Maisonpierre et al, 1997; Holash et al, 1999b). Although angiopoietin 2 and angiopoietin 
1 share a similar protein structure, their biological activities differ greatly. Angiopoietin 2, 
in contrast to angiopoietin 1, does not stimulate EC proliferation (Witzenbichler et al, 
1998). Mice overexpressing angiopoietin 2 die at embryonic day 9.5 due to a disruption in 
vessel formation (Maisonpierre et al, 1997). Similarly to angiopoietin 1, angiopoietin 2 
also binds the Tie-2 receptor, but whereas angiopoietin 1 induces phosphorylation and 
activation, angiopoietin 2 does not activate the receptor and thereby acts as a competitive 
inhibitor of angiopoietin 1 (Davis et al, 1996; Maisonpierre et al, 1997). Angiopoietin 2 
destabilizes vessel walls and promotes active remodeling; regression in the absence of 
growth factors or vessel sprouting in the presence of growth factors, most notably VEGF-A 
(Maisonpierre et al, 1997; Holash et al, 1999a; Holash et al, 1999b; Zagzag et al, 1999). 
Although early studies characterized angiopoietin 2 as antiangiogenic, this is not 
always strictly the case. In certain in vitro assays, angiopoietin 2 has been shown to have 
functions similar to angiopoietin 1. In these assays, angiopoietin 2 is able to induce Tie-2 
receptor phosphorylation (Maisonpierre et al, 1997; Kim et al, 2000). Thus, depending on 
the surroundings, angiopoietin 2 could act as a proangiogenic as well as an antiangiogenic 
growth factor. 
In addition to effects on vascular development, angiopoietin 2 seems to play a role in 
lymphatic development (Gale et al, 2002). Mice lacking angiopoietin 2 show lymphatic defects. 
These defects can be compensated and the lymphatic phenotype can be rescued if angiopoietin 1 
is placed in the angiopoietin 2 locus. These findings seem to indicate, that in addition to being 
factors in angiogenesis, both angiopoietin 2 and angiopoietin 1 play some part in 
lymphangiogenesis as agonists.  
The function of the angiopoietins, especially angiopoietin 2, in vascular 
development remains slightly controversial and seems to vary depending on the 
surrounding environment and signalling by other growth factors. Certainly more 
information is needed on the subject. 
4. Lymphangiogenic growth factors in the preterm lung 
4.1 Overview of lymphangiogenic growth factors 
Lymph sacs first appear at about week 6-7 of gestation. Prox1 (Hong et al, 2002) and 
VEGF-C are crucial for early lymphatic development. 
Other factors that may contribute to lymphatic development include VEGF-D, 
podoplanin (Schacht et al, 2003), and receptors VEGFR-3 and LYVE-1 (Banerji et al, 
1999). VEGF-D knockout mice have a decrease in VEGFR-3 positive vessels adjacent the 
muscular surface of bronchioles. However, this decrease is not large enough to change the 
 
 
 
 
23
difference between wet and dry lung weight, suggesting that VEGF-D is not crucial for 
normal lymphatic development (Baldwin et al, 2005). Also in mice, VEGF-D is evident 
from embryonic day 13.5 in the pseudoglandular stage of lung development and remains 
active until birth, but is not seen postnatally (Greenberg et al, 2002).  
Mediators contributing to the development of the lymphatic system have been 
difficult to investigate. The problem seems to center around the fact that there have been 
no specific markers for lymphatic ECs. Although VEGFR-3 is highly lymph specific later 
in development, during embryogenesis it is also expressed by blood vascular ECs. LYVE-1 
seemed to be specific for lymphatic ECs throughout development (Banerji et al, 1999), 
although this has also been placed in doubt (Gordon et al, 2008).  
4.2 Vascular endothelial growth factor C (VEGF-C) 
4.2.1 Background 
VEGF-C is a member of the VEGF family of vascular endothelial growth factors 
(Tammela et al, 2005). Together with VEGF-D, VEGF-C was the first characterized 
growth factor to induce growth of new lymphatic vessels in vivo (Joukov et al, 1996; 
Jeltsch et al, 1997; Oh et al, 1997). VEGF-C is produced as a 61 kDa pre-propeptide and is 
proteolytically processed to form a homodimer of 21 kDa, which has a high binding 
affinity for VEGFR-3 and VEGFR-2 (Joukov et al, 1996; Joukov et al, 1997). Only fully 
processed VEGF-C has the ability to bind VEGFR-2 and hence act on blood EC function, 
as well as lymphatic endothelium. Proteolytic cleavage of the immature VEGF-C molecule 
is hence an important step in the regulation of VEGF-C action (Joukov et al, 1997; Joukov 
et al, 1998). The binding affinity of the short 21 kDa form of VEGF-C to VEGFR-3 is 4-5 
times stronger than to VEGFR-2 (Makinen et al, 2001b). 
4.2.2 VEGF-C in physiological development 
During development VEGF-C is localized particularly to regions where lymphatic vessels 
sprout from embryonic veins. In these regions, VEGF-C is produced by smooth muscle. 
High levels of VEGF-C have also been detected in the developing murine mesenterium, 
lung, heart and kidney (Kukk et al, 1996). VEGF-C is essential for the embryonic 
development of the lymphatic system, as gene-targeted mice lacking the VEGF-C gene are 
embryonic lethal due to fluid accumulation in tissues. VEGF-C+/– mice survive into 
adulthood, but display severe lymphatic hypoplasia (Karkkainen et al, 2004). The 
importance of VEGF-C for the developing lymphatic vasculature is demonstrated in 
VEGF-C-/-, Prox1+ mice, where lymphatic ECs arise normally in the cardinal vein, but do 
not sprout from their initial location (Baldwin et al, 2005). 
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4.3 Vascular endothelial growth factor receptor 3 (VEGFR-3) 
Before the onset of lymphatic vascular differentiation, VEGFR-3 (fms-like tyrosine kinase-
4) is highly expressed in blood vascular ECs, but its expression becomes gradually 
restricted to lymphatic ECs after midgestation (Kaipainen et al, 1995; Kukk et al, 1996; 
Dumont et al, 1998). Mice deficient in VEGFR-3 gene expression show abnormal 
remodelling of vascular plexuses and die on embryonic day 9.5 (Dumont et al, 1998). 
Soluble VEGFR-3 in mice effectively inhibits lymphangiogenesis and leads to regression 
of existing fetal lymphatic vessels in vivo, without affecting vascular development 
(Makinen et al, 2001a). This illustrates the high lymphatic specificity of VEGFR-3 and the 
need for continuous VEGFR-3 stimulation in lymphatic development. In the adult, 
VEGFR-3 is located primarily on lymphatic ECs (Kukk et al, 1996). Missense mutations 
deactivating VEGFR-3 have been shown to lead to primary lymphedema both in humans 
and in mice (Karkkainen et al, 2000).  
Recent studies of postnatal lymphangiogenesis have shown that lymphatic 
capillaries require VEGFR-3 to be activated by soluble ligands for up to two weeks after 
birth, after which lymphatic capillaries become insensitive to VEGFR-3 inhibition. This 
indicates that after a certain period lymphatic capillaries become mature and do not depend 
on VEGFR-3 expression for continued survival (Karpanen et al, 2006). 
 
5. BPD in the 21st century 
5.1 Historical perspective on BPD 
Hyaline membranes were first described in 1903, found in the lungs of infants dying from 
respiratory distress. Little or no therapy was available for treatment of RDS with infants 
either recovering or dying by 7 days of age.  
From the 1940s onward, routine use of oxygen became common practice followed 
by positive pressure mechanical ventilation in the 1950s, and mechanical ventilation 
combined with supplemental oxygen in the 1960s. This development led to higher survival 
rates, but also to the development of a new chronic lung disorder, BPD, first described by 
Northway in 1967 (Northway et al, 1967). The condition discovered and described in the 
1960s differs greatly from the one seen today. High percentage inspiratory oxygen resulted 
in inflammation, fibrosis and smooth muscle hypertrophy in the airways (O'Brodovich & 
Mellins, 1985). 
In 2001, the diagnostic criteria were revised due to changes in BPD epidemiology, 
from the requirement of supplemental oxygen at postnatal age of 28 days to need for 
supplemental oxygen at 36 weeks postmenstrual age, in addition to a chest radiograph with 
findings characteristic of BPD (Jobe & Bancalari, 2001). 
The clinical course of BPD was originally divided into four stages: Stage I (2 to 3 
days), was essentially RDS; respiratory failure, deposition of hyaline membranes, 
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atelectasis, and metaplasia and necrosis of the bronchiolar mucosa. During stage II (4-10 
days), the infants were usually weaned from the respirator, but still needed high 
concentrations of inspired oxygen. Histological appearance of the lungs showed 
emphysema at alveolar level as well as bronchiolar necrosis. Stage III (10-20 days), was 
characterized by widespread bronchiolar metaplasia and hyperplasia, emphysematous 
alveoli and increasing atelectasis. During this stage the changes occurring began 
transforming the lung injury towards a more chronic state, BPD. 
In Stage IV (after 1 month), histology showed hypertrophy of peribronchiolar 
smooth muscle, emphysema, and separation of capillaries from alveolar epithelium by 
thickening of the basement membranes (Northway et al, 1967; Northway, 2001). 
Towards the end of the century, new forms of treatment again altered the clinical 
aspect of BPD. Surfactant replacement therapy was an important discovery which served to 
“soften” the clinical course of BPD. In addition, the use of antenatal steroids, continuous 
positive airway pressure (CPAP) to decrease time on mechanical ventilation, oxygen 
saturation monitors to minimize oxygen exposure, combined with less aggressive 
ventilation strategies, and improved nutrition all improved the clinical outcome of preterm 
infants with respect to lung morbidity. Whereas before infants typically suffered from 
severe respiratory distress during the first postnatal days now the course of the disease is 
milder with less severe symptoms (Avery & Merritt, 1991; Parker et al, 1992; Egberts et al, 
1997; Stevenson et al, 1998; Northway, 2001). This change in the clinical course of the 
disease has not decreased its occurence, only shifted it towards more immmature infants 
with more immature lungs. 
5.2 Pathogenesis of BPD; prenatal events 
The pathogenesis of BPD is considered to consist of prenatal and postnatal components. 
The main components can be seen in Figure 3. 
5.2.1 Prenatal infection and inflammation 
There is strong evidence indicating that infection and inflammation play important roles in 
the pathogenesis of BPD. An imbalance between proinflammatory and anti-inflammatory 
mechanisms in utero seems to predispose the infant for later development of BPD. 
Subclinical and clinical intrauterine infection and the inflammatory response created in the 
preterm lung are important in the etiology of preterm labor and preterm premature rupture 
of membranes (Lahra & Jeffery, 2004). 
Although prenatal infection correlates to a lower rate of postnatal RDS it also 
correlates to a higher incidence of BPD (Watterberg et al, 1996). The fetal lung does not 
normally mount inflammatory responses, and the components that contribute to a mature 
inflammatory response to injury are deficient in the fetus. The preterm fetal lung contains 
almost no macrophages or granulocytes, and host defense proteins such as surfactant 
protein A and surfactant protein D are also deficient (Stahlman et al, 2002). 
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Proinflammatory cytokines do not cross the placenta and all existing cytokines in the 
preterm lung in utero are thus synthesized there (Aaltonen et al, 2005). Cytokines are 
synthesized by alveolar macrophages, airway epithelial cells, fibroblasts, type II 
pneumocytes and ECs. Hypoxia, hyperoxia, micro-organisms, endotoxin, other bacterial 
cell wall constituents and biophysical factors such as barotrauma and volutrauma all 
activate cytokine synthesis in the preterm lung (Speer, 2006). Important proinflammatory 
cytokines include interleukin (IL) -8, tumor necrosis factor-α, IL-1 and IL-6 (Coalson et al, 
1999). The increased expression of proinflammatory cytokines could be a reflection of an 
inability of the preterm lung to regulate inflammation through anti-inflammatory cytokines 
such as IL-4, IL-10, IL-12, IL-13 and IL-18 (Jones et al, 1996; Jonsson et al, 2000; Baier et 
al, 2003; Kakkera et al, 2005; Nakatani-Okuda et al, 2005). Inflammation in the preterm 
lung has a delayed clearance rate and causes injury followed by maturation (Jobe et al, 
2000; Moss et al, 2002; Willet et al, 2002). 
 
Figure 4. The main components in the pathogenesis of BPD. 
5.2.2 Antenatal steroids 
Antenatal glucocorticoid treatment decreases the incidence of RDS while it does not seem to 
affect the incidence of BPD. This lack of effect of antenatal glucocorticoid treatment on BPD 
has been explained by the increased survival of infants mostly at risk of BPD (Crowley, 
1995; Jobe, 2000). Glucocorticoid exposure of the fetal lung upregulates numerous genes 
and downregulates others; for some genes, such as surfactant protein A, regulation is dose 
dependent, low doses upregulate and high doses suppress gene expression (Liley et al, 1988). 
Early lung maturational responses to glucocorticoids can occur in the fetal primate lung by 
midgestation. However, high or prolonged fetal exposures cause an inhibition of subsequent 
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fetal lung development. Newborn mice and rats are born with saccular lungs at term, and 
postnatal glucocorticoid treatments cause a delay in alveolar and vascular development that 
persists as the animals age (Massaro & Massaro, 2000). Repeated doses of antenatal 
glucocorticoid treatment have been shown to have a beneficial effect on lung maturation and 
growth, but at the same time an adverse effect on brain function and also contribute to 
overall growth retardation (Aghajafari et al, 2002).  
It may be that excessive exposure of the preterm lung to glucocorticoids could prime 
the lung for later insults, such as inflammation and oxygen exposure. This might be the 
underlying reason why antenatal glucocorticoids therapy has failed to decrease the 
incidence of BPD, and why antenatal steroids should be administered with care. 
5.3 Pathogenesis of BPD; postnatal events 
5.3.1 Surfactant treatment 
The introduction of widespread surfactant treatment for RDS beginning with the first 
clinical trials at the beginning of the 1980s has contributed greatly towards decreasing 
mortality and morbidity in preterm infants (Soll, 2000a; Soll, 2000b). Before the surfactant 
era, BPD was always preceded by aggressive RDS. This entailed destruction of existing 
pulmonary structures, inflammation and fibrosis, affecting infants of GA 32-36 weeks. 
Since surfactant decreased the incidence of RDS, it also led to decreased BPD among these 
more mature preterm infants. BPD was still occurring, but now in more immature preterm 
infants than before (GA 24-28 weeks). Hence, surfactant treatment is indirectly an 
important component in the new form of BPD. 
5.3.2 Postnatal infection and inflammation 
Postnatal inflammation in the lung is usually the result of continued intrauterine infection 
and inflammation combined with postnatal oxidative stress and mechanical ventilation. 
The inflammatory response injures the lung parenchyma and injured cells are removed by 
apoptosis, programmed cell death. This may result in arrested growth of the parenchyma, 
as cells removed certainly include progenitor cells or cells that are needed for cell-cell 
interactions. If such damage occurs at critical times in development, for example when the 
lung is building the framework for later alveolarization during the canalicular stage, lung 
development may be irreversibly halted (Le Cras et al, 2004; Massaro & Massaro, 2004). 
Associations between early onset systemic bacterial infections (Groneck et al, 1996; 
Groneck et al, 2001), as well as systemic nosocomial infections (Rojas et al, 1995; 
Groneck et al, 1996; Cordero et al, 1997) and the development of BPD have also been 
established. 
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5.3.3 Oxidative stress and barotrauma 
The toxicity of both oxygen and barotrauma have been shown in several studies. In term, 
ventilated neonatal piglets, treatment with hyperoxia alone causes less damage than 
hyperoxia combined with hyperventilation, but more damage than hyperventilation alone 
(Davis et al, 1991). Premature baboons equivalent to approximately GA of 30 weeks in 
humans, and ventilated with oxygen to maintain normal arterial oxygen concentrations have 
significantly less damage than those ventilated with 100% oxygen (Delemos et al, 1987).  
Two randomized trials have shown a higher incidence of BPD in groups that were 
treated with a higher inspired oxygen ratio, although the results were not completely 
conclusive (STOP-ROP trial, 2000; Askie et al, 2003). Hyperoxia seems to lead to an arrest 
in alveolarization in part mediated by changes in TGF-β-bone morphogenic protein 
signaling in the lung (Alejandre-Alcazar et al, 2007). This in turn up-regulates the gene 
expression of p53. p53 down-regulates the expression of VEGF-A, which impairs 
angiogenesis. p53 also induces the transcription of the cyclin-dependent kinase inhibitor 
p21(WAF/CIP1) mRNA. p21 activation is known to lead to cell cycle arrest and could 
possibly inhibit proliferation of lung cells (Maniscalco et al, 2005). However, this 
interesting mechanism for arrest in alveolarization is still incompletely understood and 
further study is needed to strengthen and clarify the subject. 
In an interesting study closely mimicking current state of the art treatment protocols, 
the lung pathology of premature baboons equivalent to about GA of 26 weeks in humans 
was studied. Despite treating the preterm baboons using minimal ventilatory stretch and 
limiting the amount of inspired oxygen, the premature baboons developed alveolar 
hypoplasia and hypoplastic capillaries (Coalson et al, 1999). This lung pathology is very 
reminiscent of the pathology seen in human preterm infants with a BW under 1000 g that 
succumb to BPD. This might indicate that very small amounts of oxygen and barotrauma 
could have a long lasting detrimental effect on the developing preterm lung. Recent studies 
and workshops have tried to identify the optimal ventilation strategy that allows for 
survival and improved clinical outcome whilst avoiding complications such as BPD. The 
main points of ventilatory strategies are to reduce the overall duration and need for 
mechanical ventilation by introducing milder ventilation techniques such as nasal CPAP 
(nCPAP) (Ambalavanan & Carlo, 2006). In fact, Miksch and coworkers showed that early 
introduction of nCPAP instead of conventional ventilation (Miksch et al, 2008) and 
Bhandari and coworkers that switching from convential ventilation to synchronized nasal 
intermittent positive pressure ventilation (Bhandari et al, 2007), greatly reduced the 
incidence of BPD in preterm infants while not affecting other outcomes. Also, the initial 
use of nasal intermittent mandatory ventilation instead of nCPAP was shown to decrease 
the need for intubation and hence decrease the incidence of BPD (Kugelman et al, 2007). 
However, it may be that ventilatory strategies are reaching a limit where they cannot be 
significantly improved with respect to decreasing the development of BPD. 
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5.4 Pathogenesis of BPD; genetics 
There are several known genetic factors contributing to the pathogenesis of BPD. Already 
in 1996 Parker and coworkers showed in a study on preterm twins that the BPD status in 
one twin was a highly significant predictor of BPD in the other twin (adjusted odds ratio 
(OR) = 12.3, p< 0.001), irrespective of birth order, Apgar scores or other factors (Parker et 
al, 1996). In a study on monozygotic and dizygotic twins Bhandari and coworkers 
observed a significantly higher concordance of BPD in monozygotic twins than expected 
(Bhandari et al, 2006a). A deletion in the gene for surfactant protein B was found to 
associate with higher risk for BPD (Rova et al, 2004). This association was only significant 
in singletons or presenting multiples, and became stronger after adjustment for lower BW, 
highlighting the requirement of both genetic and environmental factors for BPD to 
develop. These studies show a significant genetic susceptibility for BPD in preterm infants. 
A wide variety of candidate genes have been investigated, but no single gene has proven to 
be significant on its own. This seems logical since BPD is considered to be polygenic 
(Bhandari & Gruen, 2006). Despite the increase in knowledge within genomics, relatively 
little is known about genetic susceptibility underlying BPD, and the studies conducted have 
contained a restricted patient material. In a recent study Lavoie and coworkers (Lavoie et 
al, 2008) underlined the role of genes in the development of BPD. In twin pairs, genes 
accounted for the susceptibility for BPD in approximately 80% of cases. Clearly this is an 
area of BPD that needs further investigation. 
5.5 The new BPD; a halt in development 
BPD is characterized by persistent respiratory signs, prolonged need for mechanical 
ventilation or oxygen therapy, recurrent hospitalizations for respiratory infections and 
distress, exercise intolerance, and other problems that reach beyond childhood (McLeod et 
al, 1996). The exact incidence of BPD is difficult to assess, but recent estimates evaluate 
the incidences according to BW as follows; 52% in infants with a BW between 501 and 
750 g, 34% in infants with a BW between 751 and 1000 g, 15% in infants with a BW 
between 1001 and 1250 g, and 7% in infants with a BW between 1251 and 1500 g 
(Ehrenkranz et al, 2005). Overall, the average age of preterm infants developing BPD has 
markedly decreased since the introduction of modern treatment strategies (antenatal 
betamethasone, surfactant, ventilation and early treatment of infection). BPD is currently 
rare in infants with a BW > 1500 g and GA > 30 weeks (Ehrenkranz et al, 2005). Because 
of this temporal shift of BPD from more mature infants to infants with less developed 
lungs, the underlying mechanisms in the pathogenesis of the disease have changed. Maybe 
most importantly for the change in the pathogenesis of BPD is that histological changes 
now represent injury to the lung at an earlier (early saccular stage, GA 24-28 weeks) stage 
of development (Parker et al, 1992; Husain et al, 1998). Pathologic findings in the lungs of 
infants with “new” BPD are very different from those found in “classic” BPD. Instead of 
the destruction of already existing structures and inflammation seen in “classic” BPD, a 
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halt in development without widespread inflammation and destruction is seen in the new 
form of BPD. 
Recent evidence suggests that blood vessels in the lung actively promote normal 
alveolar development (Jakkula et al, 2000; Abman, 2001) and contribute to the 
maintenance of alveolar structures throughout life (Kasahara et al, 2000). When an infant is 
born prematurely, the normal development of the lung is disrupted. Due to advances in 
treatment, premature infants of GA 24-28 weeks survive, but at the same time are at the 
greatest risk for the development of BPD. Infants born during this stage of development 
have lungs that are in the late canalicular to early saccular stage of development. The 
initiation of the gas exchanging unit has only recently begun, with vascular vessels and 
pulmonary structures coming into contact. Thus, birth at this stage of development disrupts 
the whole base of the gas exchanging function of the lung. This is reflected by decreased 
septation and alveolarization, which in turn decreases the overall gas exchanging surface of 
the lung. The alveoli are larger in size and fewer in number (Le Cras et al, 2002). Another 
typical feature is dysmorphic vascular growth (Tomashefski et al, 1984).  
Previously, an association between abnormalities in pulmonary circulation, 
specifically pulmonary hypertension, and increased risk for development of BPD have 
been documented (Hislop & Haworth, 1990; Parker & Abman, 2003). Current results from 
both animal and clinical studies suggest that there is a link between impairment of 
angiogenesis during critical periods of development and the disruption of lung epithelial 
development, most importantly alveolarization, leading to the development of BPD. 
Support for the vascular hypothesis of BPD is extensive and has been summarized in a 
review by Thébaud and Abman (Thebaud & Abman, 2007).  
The disruption of angiogenesis disrupts alveolarization in several animal models. 
Treatment with angiogenesis inhibitors in newborn and infant rats compared to vehicle-
treated control rats clearly decrease not only vascular density, but also alveolarization and 
lung weight (Jakkula et al, 2000; Le Cras et al, 2002). Mice lacking in two out of three 
important isoforms of VEGF-A show marked decrease of not only vasculature, but also 
air-blood barriers and airspace-parenchyma ratio compared to wild type mice (Galambos et 
al, 2002). Inhibition of VEGF-A and VEGFR-2 in rats decrease angiogenesis and impairs 
alveolarization. Alveolar structures become oversimplified, resembling those seen in 
human lung pathology in BPD (Thebaud et al, 2005). Downregulation of VEGF-A and 
VEGFR-1, as well as VEGFR-2 and Tie-2 receptors, have been reported to lead to 
dysmorphic vascular development and to decrease septation and alveolarization in a way 
that is characteristic of BPD (Maniscalco et al, 1997; Bhatt et al, 2000; Bhatt et al, 2001; 
Lassus et al, 2001; Maniscalco et al, 2002).  
Prolonged exposure to hyperoxia decreases VEGF-A mRNA levels, a phenomenon 
believed to contribute to oxygen induced lung injury and impaired vascular repair 
(Johnston et al, 1996; Klekamp et al, 1999). Similarly, in newborn rabbits, VEGF-A 
mRNA expression is decreased during hyperoxia, whereas during the recovery period in 
relative hypoxia, VEGF-A expression is increased (Maniscalco et al, 1995; Maniscalco et 
al, 1997). The lungs of ventilated preterm infants show a decrease in VEGF-A and 
angiopoietin 1 mRNA, but an increase in endoglin mRNA when compared to age-matched 
controls (De Paepe et al, 2008). Higher angiopoietin 2 concentrations in TAF of human 
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preterm infants have been shown to associate with a higher risk of developing BPD (Aghai 
et al, 2008). Angiopoietin 2, predominantly exhibiting antiangiogenic action, expression 
has been found to be induced by hyperoxia. Interestingly, angiopoietin 2-/- knockout mice 
are protected against the injury caused by the hyperoxic conditions (Bhandari et al, 2006b).  
Neutralization of VEGF-A during hyperoxia clearly decreases survival in adult mice. In 
these mice overexpression of IL-13, an anti-inflammatory mediator, increases VEGF-A 
levels in bronchoalveolar lavage and this increase is even more marked in hyperoxia 
(Corne et al, 2000). However, in newborn transgenic mice neither IL-13 (Choo-Wing et al, 
2007) nor VEGF-A (Bhandari et al, 2008) has similar protective effects against the 
development of BPD. This demonstrates the disruption of normal angiogenesis in a 
hyperoxic environment and highlights the dysmorphic character of angiogensis in BPD. 
Certainly, VEGF-A expression is downregulated by hyperoxia, and yet unknown mediators 
might be able to reverse this downregulation. Thus, the role of other regulators of 
angiogenesis, such as endoglin, together with VEGF-A could act to protect the lung against 
hyperoxic injury. 
In fetal preterm lambs, intra-amniotic infusion of endotoxins markedly reduces 
VEGF-A expression as well as the expression of other important factors associated with 
proangiogenic activity in the lung (Kallapur et al, 2004). In preterm baboons prolonged 
mechanical ventilation also decreases VEGF-A levels (Maniscalco et al, 2002; Asikainen 
et al, 2006b). In summary, several factors known to contribute to the pathogenesis of BPD; 
inflammation, hyperoxia and mechanical ventilation, all alter the profile of angiogenesis in 
the lung. Indeed preterm infants with lower pulmonary concentration of VEGF-A during 
the latter part of the first postnatal week have a higher incidence of BPD (Lassus et al, 
1999; Bhandari et al, 2008). Also, in lung tissue from human infants who died from BPD, 
the typical pattern of alveolar simplification along with dysmorphic microvascular features 
are associated with a lower VEGF-A and angiopoietin 1, but higher lung endoglin mRNA 
expression (Bhatt et al, 2000; De Paepe et al, 2008). 
Upregulation of PlGF has been observed in several states of pathologic 
angiogenesis. Increased expression of PlGF in skin of transgenic mice results in a 
significant increase in number and size of skin blood vessels as well as increasing blood 
vessel permeability (Odorisio et al, 2002; Oura et al, 2003). PlGF deficiency results in a 
diminished and shortened inflammatory response which leads to reduced inflammatory 
angiogenesis and edema formation (Oura et al, 2003). PlGF also contributes to the 
pathogenesis of preeclampsia. Decreased levels of PlGF in plasma of pregnant women 
seem to increase the risk of preeclampsia, although this result remains controversial 
(Widmer et al, 2007). In a study measuring PlGF from cord plasma in preterm infants at 
birth Tsao and coworkers found higher PlGF concentrations to be associated with the 
development of BPD (Tsao et al, 2004). Thus, PlGF seems to be upregulated by 
inflammation and in turn PlGF upregulates the inflammatory response. Also, a higher 
concentration of PlGF in cord plasma at birth seems to predict the development of BPD. 
Studies on the effect of endostation and VEGF-C on lung injury in preterm infants 
have been limited. For both, current knowledge is based on mouse models focusing either 
on pathologic angiogenesis (endostatin) (Fukai et al, 2002; Li & Olsen, 2004), or 
lymphangiogenesis (VEGF-C) (Karkkainen et al, 2004). 
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In VEGF-A transgenic mice mortality rates are increased both when VEGF-A 
expression increases prenatally (Akeson et al, 2005) as well as postnatally (Le Cras et al, 
2004), in part due to increased vascular permeablity. Bhandari and coworkers 
demonstrated that the increased vascular permeability mediated by VEGF-A in transgenic 
mice is at least partly nitric oxide dependent, while effects on surfactant production are 
nitric oxide independent (Bhandari et al, 2008). Any possible intervention on angiogenesis 
needs to be carefully planned and executed in order to be both safe and effective. It seems 
that a combination of several regulatory systems could prove most effective. Certain 
studies have demonstrated improved vascular and alveolar growth in experimental BPD 
models by enhancing angiogenesis. Rats treated with exogenous recombinant human 
VEGF-A during hyperoxic conditions initially showed increased emphysema, which was 
followed by improved vascularization during the recovery period (Kunig et al, 2006a). 
Treated rats also exhibited enhanced alveolarization (Kunig et al, 2005a). Likewise, 
postnatal intratracheal adenovirus mediated VEGF-A gene therapy improves survival, 
promotes lung capillary formation, preserves alveolar development and regenerates new 
alveoli in a model for irreversible lung injury in newborn rats (Thebaud et al, 2005). In 
preterm baboons, activation of hypoxia inducible factors leads to an increase in expression 
of proangiogenic platelet-endothelial cell adhesion molecule 1 and VEGF-A but does not 
increase alveolar epithelial structures (Asikainen et al, 2006a). 
A recent study by De Paepe and coworkers shows that an initial decrease in ECs 
after brief ventilation is followed by a marked increase during prolonged ventilation in 
BPD, despite a decrease in vessel number. The study was quantitative in nature and thus 
did not look at vessel organization (De Paepe et al, 2006). Typically, a failure of septation 
also leads to a failure in microvascular maturation, an intricate process. It seems likely that 
despite the marked EC proliferation observed by De Paepe, that lack of organization and 
regulation of EC migration, proliferation and vessel formation would lead to dysmorphic 
vascular development. Animal models as well as clinical studies have been focused to 
better investigate the new form of BPD. 
Clearly there are unresolved issues regarding the pathogenesis of BPD and details 
surrounding the vascular hypothesis. However, on the basis of information currently 
available it seems clear that angiogenesis and alveolarization are closely intertwined during 
development of the functional gas-exchanging apparatus of the lung. A disturbance in 
angiogenesis will disrupt physiological alveolarization and vice versa. 
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Aims of the study 
The aim of this study was to investigate the roles of proangiogenic, antiangiogenic and 
lymphangiogenic growth factors in normal lung development as well as in the development 
of BPD by using human samples. Each growth factor was selected because of its close 
relationship to VEGF-A, known to have an established role in both normal angiogenesis 
and in the pathogenesis of BPD. 
 
By using three separate analyses: 1. immunohistochemistry on lung samples (I, II and IV), 2. 
TAF (I, II and IV), and 3. cord plasma (III) the specific aims of the study were to: 
 
1. clarify the role of PlGF, endostatin, VEGF-C, VEGFR-2, and VEGFR-3 in physiological 
lung development.  
 
2. investigate whether any of PlGF, endostatin, VEGF-C, VEGFR-2, or VEGFR-3 
participates in the pathogenesis of lung injury, specifically BPD.  
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Material and methods 
1. Material 
1.1 Ethics 
Studies I, II and IV were approved by the Ethics Committee of the Hospital for Children 
and Adolescents, University Central Hospital (Helsinki, Finland). Study III was approved 
by the Ethics Committee of the Department of Obstetrics and Gynaecology, University 
Central Hospital (Helsinki, Finland). All studies comply with the principles stated in the 
Declaration of Helsinki (2004). 
1.2 Patients in immunohistochemistry studies (I, II and IV) 
For immunohistochemistry analysis all lung tissue samples were collected between March 
1991 and June 2000. Immunohistochemistry analysis was included in studies I, II and IV. 
Study I included 39, study II 45 and study IV 48 subject samples (Table 1). 
The infants from which the samples were analyzed were divided into groups according 
to GA or time of abortion as well as lung pathology at the time of death. The diagnoses of 
these infants can be seen in Table E1 of study IV. Fetuses as well as preterm and term controls 
had macroscopically and microscopically normal lungs at the time of death. In other words, no 
hyaline membranes or macroscopical edema or inflammation, which are both indicators of 
acute lung injury; RDS, were present in the samples from these infants.  
The early RDS group consisted of preterm infants who died within 2 days of birth. 
The late RDS group consisted of preterm infants who died later than 10 days after birth but 
did not fill the criterion for BPD. BPD was diagnosed defined clinically as the need for 
supplemental oxygen at the age of 36 postmenstrual weeks in association with chest 
radiographic findings typical of BPD (Jobe & Bancalari, 2001), and post mortem 
histologically. The patients in both RDS and BPD groups died because of their lung disease. 
1.3 Patients in TAF studies (I, II and IV) 
TAF analysis was included in study I, II and IV. A total of 59 infants were enrolled 
between December 1993 and March 2002. Study I included 20, study II 59, and study IV 
54 infants. Patients were selected on the basis of development of BPD, defined clinically as 
the need for supplemental oxygen at the age of 36 postmenstrual weeks in association with 
chest radiographic findings typical of BPD (Jobe & Bancalari, 2001). Approximately half 
of the infants in the study group developed BPD while half survived without it. The BPD 
vs. no BPD group was matched with respect to GA and BW (Table 2). 
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Lactosyl ceramide (LC) has previously been demonstrated in large amounts in 
granulocytes and inflamed fetal membranes. It was measured by thin layer chromatography 
as previously described (Hallman et al, 1989). 
All the infants included were treated in the neonatal intensive care unit of the Hospital 
for Children and Adolescents, Helsinki University Central Hospital. Infants included in the 
study had to be intubated at birth because of failure to establish spontaneous ventilation. 
Infants were mechanically ventilated during the whole study period. Infants exhibiting major 
anomalies were excluded from the study. The standard protocol for treatment of the neonatal 
intensive care unit was followed in the treatment of all infants.  
1.4 Patients in cord plasma study (III) 
Samples from a study population consisting of 140 newborn infants born at the Department 
of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland 
were collected. The study population was divided and analyzed according to BW and GA; 
a VLBW group whose BW was under 1500 g and GA under 32 wk (n=92), and a healthy 
term group with BW over 1500 g and GA over 37 wk (n=48) which served as a controls. 
Analysis was done both between the groups as well as within the group. Infants whose 
mothers had pre-eclampsia or diabetes mellitus were excluded from the control group to 
ensure as healthy a control group as possible (Table 2). 
Table 1. Patient data for immunohistochemistry (I, II and IV)  
 Fetus Preterm 
control 
Term 
control 
Early 
RDS 
Late 
RDS 
BPD 
N, I 9 4 8 5 7 6 
N, II 9 5 9 7 7 8 
N, IV 10 5 10 8 7 8 
GA , I 18.1±2.6 24.6±2.9 38.9±1.7 26.0±2.1 26.8±1.7 28.2±2.3 
GA, II 18.6±2.9 24.2±2.7 39.1±2.1 26.0±2.1 26.8±1.7 27.7±2.1 
GA, IV 18.5±2.1 24.2±2.7 38.2±2.7 25.8±2.0 26.8±1.7 27.7±2.1 
BW, I 194±122 788±341 3411±608 799±464 692±151 892±177 
BW, II 226±162 698±357 3406±569 727±399 692±151 908±218 
BW, IV 224±153 698±357 3276±662 713±372 692±151 908±218 
TAD, I - 0.1±0.1 1.0±1.0 1.3±0.7 11.3±2.8 207±82 
TAD, II - 0.1±0.1 1.0±0.9 1.5±0.6 11.3±2.8 180±86 
TAD, IV - 0.1±0.1 0.8±0.8 1.4±0.9 11.3±2.8 143±88 
Abbreviations: N: number of subjects included in each group of each study, GA: gestational age expressed 
in weeks, BW: birth weight expressed in grams, TAD: time at death expressed in days. STUDY I: PlGF and 
VEGFR-2, II: endostatin, IV: VEGF-C and VEGFR-3. 
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Table 2. Patient data for ELISA (I-IV) 
 I PlGF TAF II ES TAF III ES cord IV VEGF-C TAF
 N=20 N=59 N=92 N=54 
Antenatal parameters     
Betamethasone 14 46 85 43 
Number of doses (1 vs. 2 
doses) 
7 vs. 5 26 vs. 13 54 vs. 16 32 vs. 11 
time of administration 
before delivery (days) 
6.6±6.7 5.2±5.2 5.9±8.5 5.1±5.3 
Antenatal dg.     
Chorioamnionitis  7 11 10 12 
Preeclampsia 4 15 20 17 
C-section 15 37 52 39  
Parameters reflecting 
maturity 
    
Gestational age (weeks) 27.7±2.3 27.3±2.0 27.9±2.3 27.2±1.8 
Birth weight (g) 1088±409 948±323 1015±285 920±287 
Birth weight (SDS) 0.0±1.6 -1.2±1.6 -1.2±1.4 -1.5±1.6 
L/S ratio (0-10) † 7±3 6±3 NA 6±3 
Perinatal parameters     
Apgar score at 1 min 5±2 5±2 7±2 5±2 
Indomethacin 14 42 27 40 
LC † 5 10 NA 9 
Umbilical arterial cord pH  7.30±0.07 7.31±0.08 7.28±0.09 7.29±0.10 
Umbilical arterial cord BE -2.3±3.0 -2.3±2.9 -3.0±3.0 -2.7±3.5 
Respiratory distress 
parameters 
    
aA ratio 0.16±0.14 0.22±0.21 NA 0.20±0.18 
Surfactant 19 49 28 44 
Extubation (days) 16±13 18±17 23±18 20.5±17 
FiO2 (%) 38±18 36±16 54±21 39±16 
Development of BPD 9 27 19 27 
Continuous data given as mean±SD. Definition of abbreviations: ES = endostatin, chorioamnionitis = 
clinical signs, leukocytosis (B-leuk>14x109/L), or c-reactive protein concentration in plasma > 50mg/L, NA 
= not applied, L/S = lecithin/sphingomyelin, †: fetal lung maturity was measured from a tracheal aspirate 
sample within 3 hours after birth, aA = arterial-alveolar. STUDY I: PlGF, II: endostatin, III: endostatin in 
cord plasma (VLBW group), IV: VEGF-C. 
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2. Methods 
2.1 Immunohistochemistry of lung samples (I, II and IV) 
Lung samples from all infants included in the study were collected at autopsy. The samples 
were then fixed by 10% neutral buffered formalin and immersed in formalin. Samples were 
stored in dry conditions at room temperature until use. When samples were sectioned for 
use, the slides were stained within 2 weeks after sectioning. 5 µm sections were 
deparaffinized in xylene and rehydrated through graded concentrations of alcohol and 
distilled water. The sections were then treated in a 700 W microwave oven for 4x5 min in 
Tris-EDTA solution, and the slides were cooled at room temperature for 20 min and 
washed in 1:10 PBS distilled water solution. Specific antibodies were then applied, 
discussed individually for the different studies below. Bound antibody was visualized by 
the avidin-biotin complex (ABC) immunoperoxidase technique (Vectastain, Elite ABC Kit, 
Vectastain; Vector, Burlingame, CA). Sections were incubated with the biotinylated 
second-layer antibody and peroxidase labeled ABC for 30 minutes each. All dilutions were 
made in PBS (pH 7.2) and all incubations in the ABC method were carried out in humid 
chambers at room temperature. Between each step in the staining process, slides were 
rinsed in 3 changes of PBS. Peroxidase staining was visualized with 3-amino-9-ethyl-
carbazole (A-5754; Sigma, St Louis, MO), 0.2 mg/mL in 0.05 M acetat buffer containing 
0.03% perhydrol (pH 5.09 at room temperature for 15 min. Sections were rinsed in tap 
water for 10 min. To complete the process sections were counterstained in Mayer’s 
haematoxylin, cleared in tap water and mounted in aqueous mounting medium 
(Aquamount; BDH, Poole, UK). 
Negative controls were performed by omission of the primary antibody, and a 
known positive section (human liver) for the antibody was included as a positive control. 
PlGF antibody was used at a 1:100 dilution (ab9542, rabbit polyclonal to human 
PLGF, Novus Biologicals, Inc., Littleton, CO). VEGFR-2 antibody was used at a 1:60 
dilution (AF357, R&D Systems Anti-human VEGF R2 (KDR) Antibody, R&D Systems 
Inc., MN). Endostatin antibody was used at 1:200 dilution (PK-6105, Vectastain Elite ABC 
Kit (Goat IgG), Vector Laboratories Inc., CA). Before staining with the specific antibody 
sections to be stained for VEGF-C were treated with Trizma®base-HCl (pH 8.5) in 4 
cycles of 5-min and microwaved. VEGF-C antibody was used at 1:100 dilution (Z-CVC7, 
polyclonal VEGF-C antibody, Zymed Laboratories Inc., CA) and VEGFR-3 antibody at 
1:300 dilution (SC-321, Santa Cruz Biotechnology, Santa Cruz, CA). 
2.2 Sample collection for TAF (I, II and IV) 
A standardized routine of tracheal lavage was used once daily to collect TAF samples. 
After placing 1 mL of sterile isotonic saline into the endotracheal tube, the patient was then 
manually ventilated for 3 breaths after which the trachea was suctioned twice for 5 seconds 
each. Secretions were then collected into a trap and transferred into tubes containing 500 
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I.U. of aprotinin (Tyrasol®, Bayer, Leverkusen, Germany) and 5 mg of deferoxiamine 
(Desferal®, Ciba, Basel, Switzerland). Until the time of analysis the tubes were stored at -
20°C. 
In study I, a total of 70 samples from 20 patients, in study II, a total of 223 samples 
from 59 patients and in study IV, a total of 191 samples from 54 patients all during the first 
postnatal week were collected and used for analysis. In addition, in study II 23 samples 
during week 2 and 22 samples during weeks 3 to 5 and in study IV, 13 samples during week 
2 and 23 samples during weeks 3 to 5 were collected from 6 patients who would later 
develop BPD. These samples were also included in the analysis for development of BPD. 
2.3 Assays for TAF (I, II and IV) 
All ELISA from TAF samples were performed in the laboratory facility of the Hospital for 
Children and Adolescents, University of Helsinki, Helsinki, Finland. 
PlGF was measured with the Human PlGF Immunoassay Kit (R&D Systems Inc.). 
Endostatin was measured with the Human Endostatin Immunoassay Kit (R&D Systems 
Inc.). VEGF-C was measured with the VEGF-C ELISA Kit (Zymed Laboratories Inc.). 
2.4 Analysis for dilution of the samples (I, II and IV) 
In TAF analysis, to negate the effect of dilution of the sample and thus estimate the true in 
situ pulmonary concentration of each growth factor, the concentration of secretory 
component of IgA (IgA-SC) in TAF was used. IgA-SC concentration in TAF is 
independent of capillary leak as well as respiratory distress or GA (Watts et al, 1992). The 
method was standardized by using IgA-SC standards, which were isolated from human 
colostrums, kindly provided by Dr. B. Götze-Speer and Prof. Ch. Speer (University 
Children’s Hospital, Würzburg, Germany).  
In TAF IgA-SC concentration was determined by direct ELISA as follows. 
Microtiter plates (Nunc, Roskilde, Denmark) were coated with 100 μL aliquots of 1:2000 
diluted anti-human secretory component (Dako, Glostrup, Denmark) in 50mM Na 
bicarbonate, pH 9.5 overnight at +4°C. The plates were then washed with 200 μL of 20-
mM tris-500 mM NaCl, pH 7.5 (TBS). To block unspesific protein binding the plates were 
incubated with 200 μL of 2% bovine serum albumin (BSA) in TBS. After incubation the 
plates were washed with 0.05% Tween 20 in TBS (TTBS). 100 μL aliquots of diluted TAF 
samples were then added to the wells. TAF samples were diluted to between 1:10 to 1:500 
in diluting buffer (1% BSA in TTBS). The plates were incubated overnight at room 
temperature. After incubation the plates were washed 3 times with TTBS. After washing 
100 μL of diluted (1:400) peroxidase-conjugated rabbit anti-human SC (Dako) was added 
and the plates were incubated for 4 hours at room temperature. After incubation the plates 
were washed with TTBS. After washing 100 μL of substrate solution containing 8 mg of 
orthophenylenediamine (Dako) and 5 μL of 30% H2O2 in 12 mL water was added in order 
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to develop the plates. The optical densities of the plates were read at 450 nm after 30 min 
incubation at room temperature. 
2.5 VEGF-C ELISA assaying (IV) 
We wanted to make sure that the commercial ELISA kit for VEGF-C recognized only the 
appropriate human forms of VEGF-C. In order to do this we tested the ability of the 
VEGF-C kit to recognize different spliced forms of VEGF-C. The procedure is described 
in full in the following segments. 
2.5.1 ELISA assaying 
We assayed for ability of the VEGF-C ELISA kit to recognize conditioned media from 
cells stably transfected with full length VEGF-C, mature proteolytically processed human 
VEGF-C lacking the N-terminal and C-terminal propeptides (ΔNΔC-VEGF-C) or mock 
vector, described in segment 2.5.2 and 2.5.4. We also assayed for the ability to recognize 
human full-length VEGF-C and human ΔNΔC-VEGF-C by using the conditioned media 
from the adenoviral infections with full-length VEGF-C, ΔNΔC-VEGF-C and β-
galactosidase (control), described in segments 2.5.2, 2.5.3 and 2.5.4. We finally assayed for 
recognition of recombinant human full-length VEGF-C and ΔNΔC-VEGF-C, described in 
segment 2.5.5. In summary, the ELISA kit recognized all full-length human VEGF-C 
proteins tested but not ΔNΔC-VEGF-C, mock vectors or controls. 
2.5.2 Cell culture 
For analysis of stably transfected VEGF-C, ΔNΔC-VEGF-C or mock vector, T293 cells 
were used. The cells were grown in Dulbecco’s Modified Eagle's Media in the presence of 
10% fetal calf serum, 2 mM L-glutamine, penicillin (100 U/mL) and streptomycin (100 
µg/mL) under selection with 1 ug/mL puromycin. 
For analysis of adenoviral transfected full-length VEGF-C, ΔNΔC-VEGF-C and β-
galactosidase (control), HeLa cells were used. The cells were grown in Modified Eagle’s 
Media in the presence of 10% fetal calf serum, 2 mM L-glutamine, 0.1mM non-essential 
amino acids (Sigma-Aldrich) and 1mM sodium pyruvate (Sigma-Aldrich), penicillin (100 
U/mL) and streptomycin (100 µg/mL). 
2.5.3 Generation of adenoviral vectors 
By cloning full-length human VEGF-C156S cDNA as a BamHI/NotI fragment into the 
corresponding sites of the pAD BglII vector, adenoviral vectors encoding for the full-
length human VEGF-C, ΔNΔC-VEGF-C or ß-galactosidase (control) could be generated. 
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For transfection, 293T cells were used to grow replication-deficient E1-E3 deleted 
adenoviruses. The adenoviruses were then concentrated by ultracentrifugation. Adenoviral 
preparations were then inspected and were found to contain no helper viruses, 
lipopolysaccharide, or any bacteriological contaminants. 20-50 multiplicity of infection 
adenoviruses were used to infect 70% confluent HeLa cells. The infection was carried out 
in serum-free media containing 0.2% BSA for 1 h. After infection the cells were incubated 
in Modified Eagle’s Media containing fetal calf serum for a period of 36 h. After 
incubation the conditioned media was collected and used for analysis. 
2.5.4 Immunoprecipitation and western blotting 
Protein secretion of stably transfected 293T cell lines as well as protein secretion from 
HeLa cells infected with the adenoviral vectors was verified as follows. 
Immunoprecipitation from the conditioned media was collected with anti-VEGF-C serum 
and analyzed by polyacrylamide gel electrophoresis under reducing conditions followed by 
western blotting with anti-VEGF-C serum. Results were then visualized by horse-radish 
peroxidase based chemiluminescence reaction. 
2.5.5 Generation of recombinant proteins 
Recombinant human VEGF-C and recombinant human ΔNΔC -VEGF-C proteins were 
generated as follows. The cDNA encoding the VEGF homology domain of human VEGF-
C (ΔNΔC; nucleotides 658−996) and full-length human VEGF-C (nucleotides 445−1608) 
were cloned into a baculoviral transfer vector between the sequences encoding the 
honeybee melittin signal peptide and the hexahistidine tag. Because of its dimeric nature, 
VEGF-C has two histidine tags per molecule and thus allows for very stringent washing 
conditions in the affinity chromatography. The recombinant protein was isolated from 
serum-free conditioned supernatant of HighFive cells infected with recombinant 
baculovirus with nickel nitriloacetic acid−affinity chromatography.  
2.6 Cord plasma (III) 
In study III, 140 blood samples (2.0 mL) were collected at birth into EDTA tubes from the 
cord vein. After the tubes were centrifuged (3000 rpm for 10 min) the plasma was stored at 
-20°C until analysis. Endostatin concentrations were measured with the Human Endostatin 
Immunoassay Kit (R&D Systems Inc.). 
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2.7 Statistical analyses 
StatView 5.1 (SAS Institute, Inc, Cary, NY) was used for statistical comparisons in all 
studies. For patient data values represent mean ± standard deviation (SD) whereas for 
experimental results values represent mean ± standard error of the mean (SEM). Frequency 
is used to express categorical variables. If variables exhibited skewed distribution they 
were Log10 transformed before analysis. However, values in text and tables are expressed 
in a non-transformed manner. Results were considered statistically significant when the p-
value was less than 0.05. 
For immunohistochemistry, data was analyzed by contingency table test and T-test. 
For analysis of TAF, in study I nonparametric methods were used in analyses of 
TAF because of smaller sample size. Analyses included the Mann-Whitney U-test and 
Kruskal-Wallis test. In addition simple regression analysis was used to calculate 
correlations.  In studies II and IV student’s t-test was used to test differences between 
unpaired items. One-way ANOVA with Bonferroni post-hoc test was used to compare 
differences between groups. To compare frequency distributions between groups the chi-
square test was used. Simple and multiple regression analyses were used to further analyze 
correlations.  
In study III the same analyses as for TAF in studies II and IV were used. In addition, 
multiple regression analysis was used to analyze factors explaining endostatin 
concentrations and logistic regression analysis was used to analyze associations between 
the development of BPD and endostatin concentration. 
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Results 
1. Growth factors and receptors in the perinatal period 
1.1 Immunohistochemistry (I, II and IV) 
Gender or post-mortem time to autopsy did not influence the results in 
immunohictochemistry analyses in any of the studies. 
1.1.1 PlGF (I) 
PlGF staining was seen throughout the perinatal period in bronchial epithelium. Both larger 
bronchi as well as smaller bronchioli displayed positivity. Apical and cytoplasmic parts of 
the cell both stained uniformly. Staining in alveolar epithelium was largely restricted to 
fetuses and preterm infants. Indeed, distal airway positivity for PlGF associated both with 
lower GA (p=0.0003) as well as lower weight at time of abortion or lower BW (p=0.0060). 
Distribution patterns within the cells differed between fetuses and preterm infants; staining 
in fetuses was seen apically whereas staining in preterm infants was more evenly 
distributed (I).  
Some macrophage positivity was seen in PlGF throughout the perinatal period (I). 
1.1.2 Endostatin (II) 
Positively staining ECs were seen throughout the perinatal period. Positively staining 
cuboidal epithelial cells were seen in 7 out of 9 fetuses with preterm or term controls 
exhibiting no epithelial positivity. No positively staining macrophages were seen in 
fetuses, but 2 preterm and 2 term controls stained positive (II). 
1.1.3 VEGF-C (IV) 
VEGF-C staining was seen in bronchial epithelium throughout the perinatal period. In most 
cases, positivity was observed in all bronchial structures in which most of the bronchial 
cells stained positively. Uniform and strong intensity staining was seen apically and less 
intense and more scattered staining in areas not adjacent to lumen. In 8 fetuses VEGF-C 
staining was observed in alveolar epithelium. During later stages of development no 
alveolar epithelial staining was seen. In most of the positive cases, staining was visible in 
most of the alveoli in which staining was seen in type-II pneumocyte resembling cells. 
Staining of VEGF-C in macrophages remained negative throughout the perinatal period 
(IV). 
 
 
 
 
43
1.1.4 VEGFR-2 (I) 
VEGFR-2 staining was seen in vascular endothelium in 18 of the 21 cases perinatally. A 
pattern for VEGFR-2 staining was evident; lower GA (p=0.024) and lower weight at time 
of abortion or BW (p=0.024) associated with positively staining venous endothelium, 
whereas higher GA (p=0.021) and higher weight at time of abortion or BW (p=0.019) 
associated with positively staining arterial endothelium. VEGFR-2 staining was seen 
additionally in lymphatic resembling structures in 7 of the 21 cases. In addition to 2 term 
control samples being positive, positive lymphatic endothelial staining was seen mostly in 
fetuses, with 5 out of 9 fetal samples being positive (I). 
1.1.5 VEGFR-3 (IV) 
Staining for VEGFR-3 was observed in all samples in lymphatic endothelium adjacent to 
vascular endothelium (IV). 
1.2 TAF (I, II and IV) 
The mean concentration of each growth factor during the first postnatal week was used for 
statistical analysis in TAF studies. 
1.2.1 Growth factor concentrations postnatally 
Mean PlGF concentration during the first postnatal week was stable (I). Mean endostatin 
concentration decreased during the first postnatal week. During week 2 it increased 
slightly, and decreased again during postnatal weeks 3-5 (II). Mean VEGF-C concentration 
decreased during the first postnatal week. VEGF-C protein expression then stabilized 
during week 2, and again decreased during weeks 3 to 5 (IV). VEGF-A and VEGF-D were 
analyzed in conjunction with VEGF-C concentrations. VEGF-D concentrations in the 
samples were below the measurement threshold. Also, no correlation between VEGF-A 
and VEGF-C concentrations were found (p=0.28). 
1.2.2 Association of growth factor concentrations to parameters reflecting lung 
development 
All studied antenatal, perinatal parameters as well as parameters reflecting maturity are 
shown in Table 3. Delivery by C-section correlated with higher PlGF levels (p=0.049). 
However, no correlations were found between BW, GA, pH or base excess (BE) and PlGF. 
Higher endostatin concentration associated with delivery by C-section (p=0.012), and also 
correlated with low BW (p=0.043) but not GA, pH or BE (Table 3). Higher concentrations 
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of VEGF-C correlated with lower BW, (p=0.004), as well as higher umbilical cord pH 
(p=0.038), but not GA or BE (Table 3, IV). 
1.3 Cord plasma (III) 
In the healthy term infant group none of the clinical parameters presented in Table 2 
correlated with endostatin concentrations. Endostatin concentration in VLBW infants was 
lower than in healthy term infants (p<0.0001) (Figure 5). 
 
Figure 5. Endostatin concentration in cord plasma is significantly higher in term than in VLBW infants. 
Horizontal lines indicate mean. Janér et al. Pediatrics 2009; in press, reprinted with permission of the copyright 
holder. 
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Table 3. Results of ELISA of growth factors and association to clinical parameters (I-IV) 
 I 
PLGF 
II 
ES 
III 
ES cord 
IV 
VEGF-C
 N=20 N=59 N=92 N=54 
Antenatal parameters     
Betamethasone NS ↑, * NS ↑, * 
number of doses (1 vs. 2 doses) NS NS NS ↑, ** 
time of administration pre delivery (days) NS NS NS ↓, * 
Antenatal dg.1     
Chorioamnionitis vs. preeclampsia NA ↓, ** NA ↓, * 
Chorioamnionitis vs. no ant. dg. ↓, * ↓, *** NS ↓, * 
Preeclampsia vs. no ant. dg. NS NS NS NS 
C-section + vs. - ↑, * ↑, * NS NS 
Parameters reflecting maturity     
Gestational age (weeks) NS NS NS NS 
Birth weight (g) NS ↓, * NS ↓, ** 
Birth weight (standard deviation) NS NS NS NS 
L/S ratio (0-10) † NS ↓, * NA NS 
Perinatal parameters    
Apgar score at 1 min NS NS NS NS 
Indomethacin NS NS NS ↓, * 
LC † ↓, * ↓, * NA ↓, ** 
Umbilical cord arterial pH  NS NS ↓, * ↑, * 
Umbilical cord arterial BE NS NS ↓, ** NS 
Respiratory distress parameters    
aA ratio NS NS NA NS 
Surfactant NS NS NS NS 
Extubation (days) NS NS NS NS 
FiO2 (%) NS ↑, * ↑, * NS 
Development of BPD NS NS ↑, *  NS 
Continuous data given as mean±SD. Definition of abbreviations: ES = endostatin, NA = not applied, NS 
= not significant, chorioamnionitis = clinical signs, leukocytosis (B-leuk>14x109/L), or c-reactive protein 
concentration in plasma > 50mg/L, L/S = lecithin/sphingomyelin, †: fetal lung maturity was measured 
from a tracheal aspirate sample within 3 hours after birth, aA = arterial alveolar, p<0.05 = *, p<0.01 = 
**, p<0.001 = ***, ↑ = associating or correlating with higher concentration, ↓ = associating or 
correlating with lower concentration. 1In studies III and IV chorioamnionitis and preeclampsia were 
analyzed as follows: chorioamnionitis vs. preeclampsia and no antenatal dg. and preeclampsia vs. 
chorioamnionitis and no antenatal dg, STUDY I: PlGF, II: endostatin, III: endostatin in cord plasma 
(VLBW group), IV: VEGF-C. 
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1.3.1 Association of endostatin concentrations to parameters reflecting lung 
development 
In VLBW infants endostatin concentrations showed no correlation with GA (p=0.91), BW 
(p=0.49) or relative BW (p=0.80). Higher endostatin concentration associated with both 
lower umbilical cord pH (p=0.022) as well as lower BE (p=0.0039). In multiple regression 
analysis after adjustment for GA, relative BW and impaired umbilical artery flow the 
associations between pH and BE and endostatin remained statistically significant. 
2. Growth factors and receptors in lung injury in preterm infants  
2.1 Immunohistochemistry (I, II and IV) 
2.1.1 PlGF (I) 
PlGF staining was seen evenly in epithelium as well as in macrophages in the RDS and 
BPD groups. More staining was observed in bronchial than in alveolar epithelium. 
However, no statistically significant differences in staining existed between the groups (I). 
2.1.2 Endostatin (II) 
Endostatin positivity was observed in ECs in all RDS and BPD cases. In early RDS neither 
epithelial cell nor macrophage staining was observed. However, in late RDS positive staining 
bronchiolar epithelial cells (2/7) as well as alveolar epithelial cells (2/7) in addition to 
alveolar macrophages (5/7) were seen. In BPD, positivity was observed in alveolar epithelial 
cells (3/8) as well as alveolar macrophages (5/8) (II). 
2.1.3 VEGF-C (IV) 
VEGF-C staining was seen in bronchial epithelium in all samples of preterm infants in the 
RDS and BPD groups. Positivity was observed in the same manner as previously 
mentioned during the perinatal period. Staining in alveolar epithelium was seen in late 
RDS in 1 case and in BPD in 2 cases. 
Additionally staining was seen in alveolar macrophages in 2 late RDS cases and in 4 
BPD cases. In these samples, macrophages were found in clusters and in each positive case 
more than 50% of the macrophages stained positively for VEGF-C (IV). 
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2.1.4 VEGFR-2 (I) 
VEGFR-2 staining between the groups revealed that overall capillary positivity was over 
60%, except in the BPD group, where positivity was only 33%. Subsequently capillary 
VEGFR-2 positivity associated with lower postnatal age of death (p=0.0034) (I). 
2.1.5 VEGFR-3 (IV) 
No difference between the groups was seen for VEGFR-3 staining. 
2.2 TAF (I, II and IV) 
Subsequent development of BPD did not associate with VEGF-C, PlGF or endostatin 
concentrations directly. 
2.2.1 PlGF (I) 
Lower levels of PlGF correlated with chorioamnionitis (p=0.015), as well as LC positivity 
(p=0.027) (Table 3). 
2.2.2 Endostatin (II) 
Higher endostatin associated with administration of antenatal betamethasone (p=0.019), well as a 
higher FiO2 (p=0.024). LC positivity (p=0.029), higher lecithin sphingomyelin ratio, a measure 
of lung maturity, (p=0.055) and chorioamnionitis on the other hand associated with lower 
endostatin concentrations. The association of chorioamnionitis and endostatin was statistically 
significant both when chorioamnionitis was compared only to preeclampsia (p=0.010) in 
addition to cases with preeclampsia as well as no antenatal diagnosis (p=0.001) (Table 3). 
2.2.3 VEGF-C (IV) 
Higher VEGF-C concentrations associated with administration of antenatal betamethasone 
(p=0.046), a higher number of antenatal betamethasone doses (p=0.01) as well as administration 
of betamethasone closer to birth (p=0.046). LC positivity (p=0.002) as well as indomethacin 
treatment (p=0.016) both associated with lower VEGF-C concentrations (Table 3). Multiple 
regression analysis for VEGF-C was performed by inclusion of all significant parameters after 
which all nonsignificant parameters were withdrawn. Three significant parameters remained: 
time elapsed between antenatal betamethasone administration and birth (p=0.013), presence of 
LC (p=0.047), and treatment with indomethacin (p=0.007). 
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2.3 Cord plasma (III) 
2.3.1 Association of endostatin concentrations to the development of BPD 
Higher endostatin concentration associated with a higher FiO2 (p=0.027) and also directly with 
the development of BPD (p=0.029) (Figure 6). We assessed whether endostatin concentrations 
would predict the development of BPD by performing a logistic regression analysis in the 
VLBW group. A 1-SD higher endostatin concentration was associated with a 1.76-fold higher 
OR (95% confidence interval 1.04-2.99) for BPD. GA was a strong predictor of the development 
of BPD: a 1-week higher GA was associated with an OR of 0.40 (95% confidence interval 0.26-
0.61). When we adjusted the analysis of endostatin concentrations for GA, the OR for BPD was 
higher: a 1-SD higher endostatin concentration was associated with a 5.54-fold OR (95% 
confidence interval 1.82-16.91). This association remained statistically significant after further 
adjustment for gender, umbilical cord pH, relative BW (SD), impaired umbilical artery flow, 
postnatal sepsis, patent ductus arteriosus and RDS. 
 
Figure 6. Endostatin concentration in cord plasma of VLBW infants. Higher endostatin concenentration associates 
with an increased risk to later develop BPD. Horizontal lines indicate mean. Janér et al. Pediatrics 2009; in press, 
reprinted with permission of the copyright holder. 
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Discussion 
It has become accepted that the arrest of development of vascular structures because of 
premature birth is an important factor in the development of BPD (Jobe, 1999; Abman, 
2001). The lung at this stage normally acts to extend, shape and multiply the developing 
alveoli and associating capillaries, but is forced into a new dynamic environment. Instead 
of continuing normal development, the lung has to adapt to become a gas-exchanging 
organ prematurely. This situation changes the surroundings of the preterm lung, and it 
comes into contact with factors that it is not equipped to cope with, and which are 
commonly associated with the development of BPD, such as inflammation and distension 
of the airways in addition to oxygen. 
Since the development of BPD is considered to be a consequence of the arrest of the 
development of the vascular structures of the lung, it seems logical to assume that a 
disturbance in the balance of proangiogenic and antiangiogenic factors as well as 
lymphangiogenic factors might exist in developing BPD. We wanted to study such growth 
factors to increase our understanding of normal lung development as well as the 
development of BPD.  
Our material consisted of samples gathered from patients receiving treatment at the 
Hospital for Children and Adolescents in the Helsinki University Central Hospital. The 
advantage of having a human material was that we were able to draw accurate conclusions 
about the presence and distribution of each growth factor during human lung development. 
Also, since accurate and complete patient journals were at hand we could assess the effect 
of a broad range of clinical parameters associated with BPD on growth factor 
concentrations. The limitations of the clinical material were that it was fairly small and can 
never be as controlled as an animal model. For TAF, no comparison with healthy controls 
could be made since healthy term patients are not intubated for several days postpartum. 
1. Growth factors during lung development 
PlGF and VEGFR-2 are both known to act in a proangiogenic fashion. PlGF was seen 
throughout development in lung epithelium as well as at a constant concentration during the 
first postnatal week in TAF (I). Distal staining in alveolar and cuboidal epithelium correlated 
with lower GA (I). The expression pattern for PlGF was to be expected due to the fact that 
VEGFR-1, the main receptor for PlGF, has been shown to be expressed in a similar way 
(Lassus et al, 2001). This suggests that at least during later stages of development PlGF 
asserts its effects mainly on conducting airways. There was no correlation between lower GA 
and higher PlGF concentration in TAF (I). PlGF-/- mice have been shown to exhibit normal 
vascular development (Carmeliet et al, 2001) and it seems despite clearly playing some part 
that PlGF might not be critical for normal lung development. 
Previously, no study on VEGFR-2 expression in the human lung had been 
published. We were able to show that VEGFR-2 staining between different types of 
endothelium varied during development (I). Interestingly, we detected some VEGFR-2 
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expression in lymphatic endothelium, mostly in fetuses. Additionally, in immature lungs 
more venous staining whereas in mature lungs more arterial staining was seen (I). VEGFR-
2 plays a role early during development in EC commitment as well as being the main 
receptor for VEGF-A mediated proangiogenic action (Shalaby et al, 1997; Hidaka et al, 
1999; Schuh et al, 1999,). We interpreted the switch of VEGFR-2 staining between 
lymphatic and venous endothelium early in development to arterial endothelium later in 
development as a reflection of the ongoing differentiation and activity of different 
endothelia. In fact, during early development there seems to be a certain overlapping of 
vasculo-, angio- and lymphangiogenesis; in mice, VEGFR-2 has an essential role in the 
development of hematopoietic cells and ECs (Shalaby et al, 1995) and has previously been 
detected on lymphatic ECs (Makinen et al, 2001a). 
VEGF-C is recognized as a lymphangiogenic growth factor. VEGF-C+/- 
heterozygous knockout mice develop cutaneous lymphatic hypoplasia and lymphedema, 
and VEGF-C-/- homozygous knockout mice do not survive until birth and exhibit chylous 
fluid accumulation in tissues (Karkkainen et al, 2004). However, during early development 
VEGF-C binds VEGFR-2 in addition to VEGFR-3 (Joukov et al, 1996), and may play a 
role in the development of the vascular tree (Dumont et al, 1998). Also, VEGFR-3, which 
later in development is strictly lymphangiogenic, is vital to venous development in mice 
lung (Dumont et al, 1998). 
Similarily to PlGF staining, all fetuses and infants exhibited VEGF-C staining in 
bronchial epithelium, whereas alveolar staining was seen mostly in fetuses (IV). Staining 
for VEGFR-3 protein was observed in all samples from fetuses to term infants in lymphatic 
endothelium adjacent to vascular structures, however, no vascular staining was seen (IV). 
The fetuses included in the study were of GA 18.5±2.1 weeks and it seems if any VEGFR-
3 vascular affinity does occur, it would occur at an earlier period of development. The 
commercial ELISA used was initially assayed for the ability to recognize only full length 
VEGF-C, not spliced forms of the protein. The concentration of VEGF-C in TAF was 
highest during the first 2 postnatal days, after which VEGF-C levels decreased during the 
first postnatal week (IV). Further, in cord plasma VEGF-C concentrations at birth were 
significantly higher in term than in preterm infants (Janér, et al, unpublished results). Since 
VEGF-C staining was seen throughout development in epithelium, the decrease in VEGF-
C protein levels in the lungs of preterm infants postnatally could be interpreted to have 
adverse effects on the developing lymphatic vasculature. 
Endostatin acts in concert with proangiogenic growth factors such as VEGF-A, and 
seems to model and guide the developing vasculature (Abdollahi et al, 2004; Jia et al, 
2004). Mouse models indicate that while endostatin does play a role in physiological 
angiogenesis, it is not critical for survival. Endostatin knockout mice have a normal 
lifespan, and apart from ocular abnormalities, exhibit no major vascular abnormalities. A 
more proangiogenic environment in these mice is suggested by the fact that aortic explants 
show a twofold increase in the number and length of microvessels (Li & Olsen, 2004). 
Immunohistochemical staining of endostatin exhibited a pattern reminiscent to that of 
VEGF-C and PlGF; staining was more abundant during earlier stages of development; 
fetuses exhibited endostatin staining in endothelium as well as in epithelium, whereas at 
term no positively endostatin staining epithelium was seen (II). Endostatin protein was 
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found consistently in TAF in preterm infants. As with VEGF-C, the concentration was 
highest immediately postpartum decreasing during the first postnatal week (II) and in cord 
plasma endostatin concentrations at birth were significantly higher in term than in preterm 
infants (III). On the basis of these findings it seems that endostatin plays a role in normal 
angiogenesis during all stages of lung development. Previously the expression of EMAP-II, 
an antiangiogenic factor, was shown to vary greatly in mice during lung vascularization 
(Schwarz et al, 1999a). Similarly, endostatin seems to exert its action at different times 
during development. We cannot draw any conclusions on endostatin activity during 
development, but the fact that concentrations increase closer to term might indicate that 
endostatin has a time of action near term and possibly after birth in normal vascular 
development. This timepoint coincides with the period of alveolarization, in which precise 
angiogenic growth is important. 
Thus, it seems that VEGF-C, endostatin and to a lesser extent PlGF are important 
growth factors during lymphangiogenesis and angiogenesis in normal lung development. In 
addition, VEGFR-2 seems to have a strong role in the developing endothelium to direct the 
proangiogenic action of VEGF-A. VEGFR-3 was seen to mediate lymphangiogenic action 
exclusively. A disturbance in the expression or action of any one of these growth factors or 
receptors could have adverse effects on the developing human lung.  
2. The role of growth factors in lung injury 
BPD is a multifactorial disorder. Several clinical parameters known to be associated with 
BPD were analyzed in the TAF and umbilical cord studies in addition to BPD (I, II, IV).  
Prepartum and postpartum inflammation is associated with BPD. Initiation of 
ventilation causes injury in the lung parenchyma, which leads to further release of 
proinflammatory cytokines. The cytokines in turn activate and attract neutrophiles and 
phagocytes to the site of injury (Jobe & Bancalari, 2001; Turunen et al, 2006). PlGF is also 
associated with recruitment of inflammatory cells (Khurana et al, 2005) and has been 
shown to induce pathologic angiogenesis in the adult by assisting VEGF-A (Carmeliet et 
al, 2001; Kumazaki et al, 2002). In addition, VEGF-A expression is increased in the lung 
prenatally in response to inflammation (Lassus et al, 1999). Also, a higher PlGF 
concentration in cord plasma of preterm infants has been shown to be associated with the 
development of BPD (Tsao et al, 2004). Considering this background we expected to find 
an elevation in PlGF concentrations in preterm infants later developing BPD. Be that as it 
may, such an elevation in concentration amongst our study group was not seen. In fact, 
infants born from pregnancies complicated by chorioamnionitis or preterm premature 
rupture of the membranes, and those who were positive for LC had lower PlGF in TAF 
during the first postnatal week (I).  Thus, we could not find evidence that PlGF assists 
VEGF-A in angiogenesis in the human perinatal lung even during inflammation as we 
would have expected. On the basis of our findings it seems that the role of PlGF in the 
development of BPD is marginal. However, this issue remains open for further 
investigation. 
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VEGF-C immunohistochemistry revealed that macrophages stained positively only 
in late RDS and BPD (IV). This is in accordance with experimental data demonstrating that 
lymphangiogenesis seems to be driven by VEGF-C and VEGF-D derived from 
inflammatory cells that migrate into the airways (Baluk et al, 2005). Maternal 
chorioamnionitis and the presence of LC in TAF both associated with lower, whereas 
treatment with antenatal glucocorticoids was associated with higher VEGF-C levels in 
TAF (IV).  In the preterm infant administration of glucocorticoids prior to birth induces 
lung maturation (Jobe, 2001). Prenatal inflammation in utero has also been associated with 
accelerated lung development (Hallman et al, 1989; Bry & Lappalainen, 2001). However, 
when inflammation continues postnatally it is associated with an impairment in lung 
development and may possibly lead to the development of BPD (DeSa, 1969; Watterberg 
et al, 1996; Speer, 2006). Thus, we conclude that the increase in VEGF-C levels seen in 
association with glucocorticoid treatment (IV) may be part of the accelerated maturation 
process of the lung. However, the lower TAF concentration of VEGF-C that associated 
with prenatal inflammation (IV) is interpreted as harmful for continued postnatal lymphatic 
development. This may lead to hypoplastic lymphatic structures, impairing the ability of 
the preterm lung to clear excess fluid accumulated either due to the treatment of the clinical 
symptoms of the patient or the development of BPD or both. It may be that the increased 
VEGF-C positivity seen in macrophages in the late RDS and BPD groups (IV) is a 
reflection of the preterm lung trying to increase lymphatic development to try to correct the 
situation.  
Lower endostatin concentration in TAF was found in cases with maternal 
chorioamnionitis as well as associated with LC positivity (II). As discussed above, 
inflammation accelerates lung maturation, but also disrupts the continued physiological 
vascular development of the lung. We consider the decrease in endostatin concentrations in 
association with inflammation to be a reflection of the maturation process of the lung. In 
addition, inflammation seems to tip the angiogenic environment of the lung towards a more 
proangiogenic surrounding as seen by the decrease in endostatin concentrations and the 
previously reported increase in VEGF-A concentrations in TAF (Lassus et al, 1999). 
The need for higher FiO2 was found to correlate with higher endostatin 
concentration in TAF (II). This same correlation also existed in cord plasma in preterm 
infants (III). Previously higher oxygenation has been found to associate with BPD (STOP-
ROP trial, 2000), and mechanical ventilation in addition to the direct effects of oxygen are 
part of the pathogenesis of BPD (Coalson et al, 1999; Charles et al, 2004; Chu et al, 2004). 
It is also known that endostatin downregulates several important signalling pathways in 
human microvascular endothelium associated with proangiogenic activity (Abdollahi et al, 
2004). In cord plasma, a higher concentration of endostatin was associated with the 
development of BPD (III). In a logistic regression analysis this association remained 
statistically significant after adjustment for factors known to be associated with BPD (III). 
In immunohistochemistry, late RDS and BPD cases displayed positive endostatin staining 
in epithelial cells as well as in macrophages. This pattern of protein expression was unique 
for these groups and could be seen neither in controls nor in early RDS cases (II). It seems 
that with the progression of lung injury the protein expression of endostatin is upregulated 
and appears in cells normally dormant for endostatin expression at that point in time. When 
 
 
 
 
53
comparing the endostatin expression pattern with that seen in VEGFR-2, almost a reversal 
of the results is seen. VEGFR-2 staining was fairly constant throughout the groups (I). 
However, staining of capillary and septal endothelium was markedly decreased in BPD (I). 
VEGFR-2 expression is guided by VEGF-A (Gerhardt et al, 2003; Hiratsuka et al, 2005) 
and lower levels of VEGF-A in TAF during the latter part of the first postnatal week 
correlates to the development of BPD (Lassus et al, 1999; Bhandari et al, 2008). VEGFR-2 
deficient mice fail to develop blood islands resulting in severely impaired vasculogenesis 
(Shalaby et al, 1995). In addition, in rats, hyperoxia leads to decreased mRNA and later 
protein expression of VEGF-A and VEGFR-2, and results in diminished alveolarization 
(Hosford & Olson, 2003). VEGFR-2 is the primary receptor through which VEGF-A 
mediates its proangiogenic action. We feel that the decreased VEGFR-2 expression in 
septal capillaries is a sign of the dysregulation of vascular development that is 
characteristic of BPD.  
In conclusion, the pattern of VEGFR-2 and endostatin protein expression illustrates 
the unbalanced situation that exists between proangiogenic and antiangiogenic growth 
factors in the development of BPD. Further, a higher concentration of endostatin in the 
preterm lung might play a role in the pathogenesis of BPD. This is strengthened by the fact 
that a higher endostatin concentration in cord plasma of preterm infants predicts the 
development of BPD. 
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Conclusions 
All studied growth factors; PlGF, endostatin and VEGF-C, as well as receptors 
VEGFR-2 and VEGFR-3 were seen consistently throughout human lung development. In 
addition PlGF, endostatin and VEGF-C were found postnatally in TAF and cord plasma 
and the concentrations in term infants were higher than in preterm infants for endostatin. 
This supports the role of endostatin and VEGF-C and to a lesser extent PlGF in normal 
vascular development of the lung. VEGFR-2 was shown for the first time to be expressed 
in the human lung during development. VEGFR-2 seems to have a strong role in the 
developing endothelium as a proangiogenic mediator of VEGF-A activity. VEGFR-3 was 
seen to mediate lymphangiogenic action exclusively. A disturbance in the expression or 
action of any one of these growth factors or receptors could have adverse effects on the 
developing human lung. 
 
We found no connection between PlGF, VEGF-C, and VEGFR-3 and the 
development of BPD. On the other hand, both endostatin and VEGFR-2 seem to be 
important in the development of BPD. This was illustrated by the disruption of VEGFR-2 
staining in capillary and septal endothelium seen in the BPD group, as well as the increase 
in endostatin concentrations both in TAF and cord plasma that associated with BPD. This 
is in agreement with previous studies where preterm infants developing BPD had lower 
concentrations of VEGF-A in TAF postnatally. There thus seems to be a shift in the 
angiogenic balance towards a more antiangiogenic environment in BPD. These findings 
underline the vascular hypothesis of BPD, which states that the disorder is caused by an 
arrest in the vascular development of the preterm lung.  
 
In summary, endostatin, VEGFR-2 and to a lesser extent PlGF play a role in 
physiological angiogenesis, whereas VEGF-C, VEGFR-3 and early during development 
VEGFR-2 play a role in lymphangiogenesis in the human lung. Additionally endostatin 
and VEGFR-2 participate in the pathogenesis of BPD, reflecting the impairment in 
vascular development that is characteristic for the disorder. 
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Yhteenveto (Finnish summary) 
Raskausviikolla 24-28 syntyneen keskosen keuhkojen kypsymättömyys altistaa 
keuhkovaurioon, bronkopulmonaaliseen dysplasiaan (BPD), joka kehittyy n. 30 prosentille 
pikkukeskosista. BPD:n kehittymiseen vaikuttavat osaltaan ainakin infektiot, tulehdus, 
hengitysilman hapen suora toksisuus ja sisäänhengityksen liian korkean paineen aiheuttama 
mekaaninen vaurio. BPD johtaa keuhkojen kehityksen merkittävään hidastumiseen.  
Monet kasvutekijät vaikuttavat keuhkojen verisuonituksen kehitykseen ja BPD:ssa 
kasvua säätelevien tekijöiden ja niiden vastavaikuttajien välillä vallitsee epätasapaino. 
Tärkein verisuonten kasvuun vaikuttava tähän asti löydetty kasvutekijä on vascular 
endothelial growth factor A (VEGF-A). VEGF-A on elintärkeä normaalille 
verisuonikehitykselle, sillä jo yksi pistemutaatio VEGF-A-geenissä johtaa sikiöaikaiseen 
kuolemaan. Keuhkojen VEGF-A-pitoisuus on korkea syntymän jälkeen, mutta matalampi 
ensimmäisen syntymänjälkeisen viikon loppupuolella niillä keskosilla, joille myöhemmin 
kehittyy BPD. Tätä taustaa vasten väitöskirjatyön tavoitteena oli tutkia VEGF-A:n 
liittyvien kasvutekijöiden placental growth factor:n (PlGF), endostatiinin sekä VEGF-C:n 
yhteyttä keuhkojen kehitykseen ja BPD:n.  
Työ koostuu kolmesta osa-analyysista. Ensimmäistä osa-analyysia varten kerättiin 
menehtyneiden ihmissikiöiden ja lasten keuhkokudosnäytteitä, Helsingin Yliopiston Lasten 
ja Nuorten Sairaalassa vuosina 1991-2000 hoidetuista potilaista. Näytteistä normaalia 
keuhkojen kehitystä edustivat keskenmenneiden raskauksien sikiöt (raskausviikot 16-20), 
keskosina syntyneet (raskausviikot 24-32) ja täysiaikaisina syntyneet (raskausviikot 38-
42). Kaikilla potilailla oli kuolinhetkellä normaalisti kehittyneet keuhkot ja keuhkokudos 
oli näytteissä normaalia. Lisäksi näytteitä kerättiin keuhkovaurioon menehtyneiltä pieniltä 
keskosilta. Sairaiden keskosten osalta ryhmät jaettiin akuuttiin (aikainen RDS, kuolinaika 
0-2 päivää syntymästä), subakuuttiin (myöhäinen RDS, kuolinaika 3-10 päivää 
syntymästä) sekä krooniseen keuhkovaurioon (BPD).  
Toista osa-analyysia varten määritettiin kasvutekijäpitoisuuksia pikkukeskosten 
imulimanäytteistä ensimmäisen viikon aikana syntymän jälkeen ELISA-menetelmällä. 
Aineisto valittiin niin, että noin puolelle potilaista myöhemmin kehittyi BPD.   
Kolmatta osa-analyysia varten endostatiinipitoisuus määritettiin napaverestä ELISA-
menetelmällä 92 pikkukeskosesta ja 48 täysiaikaisena syntyneestä lapsesta syntymän 
yhteydessä. 
Ensimmäisessä osa-analyysissa kaikki tutkitut kasvutekijät ja reseptorit ilmenivät 
kaikissa keuhkokehityksen vaiheissa. Keuhkokehityksen aikaisemmassa vaiheessa 
epiteelisoluissa (PlGF, endostatiini ja VEGF-C) ja endoteelisoluissa (endostatiini) 
havaittiin värjäytymistä kauttaaltaan keuhkoissa, kun taas kehityksen myöhemmässä 
vaiheessa värjäytyminen rajoittui keuhkojen ylempiin osiin (PlGF ja VEGF-C). VEGFR-
3:ta havaittiin keuhkokehityksen kaikissa vaiheissa ja ainoastaan imusuonirakenteissa. 
Keuhkokehityksen aikaisemmassa vaiheessa VEGFR-2:ta havaittiin imusuonten- ja 
laskimoiden endoteelisoluissa, kun taas kehityksen myöhemmässä vaiheessa VEGFR-2:n 
ekspressio rajoittui valtimoiden endoteelisoluihin. Myöhäisessä RDS- ja BPD-ryhmässä 
joka toisessa näytteessä havaittiin endostatiinia keuhkorakkuloiden epiteeli- ja 
makrofagisoluissa. VEGF-C:tä havaittiin keuhkorakkuloiden makrofageissa ainoastaan 
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myöhäisessä RDS- ja BPD-ryhmissä. VEGFR-2:ta havaittiin tasaisesti ryhmien välillä. 
Poikkeuksena BPD-ryhmän hiussuonten endoteelisoluissa VEGFR-2 puuttui joka toisesta 
näytteestä. 
Toisessa osa-analyysissa pikkukeskosten imulimanäytteiden PlGF-pitoisuus pysyi 
vakaana, kun taas endostatiini- ja VEGF-C-pitoisuudet vähenivät ensimmäisen elinviikon 
aikana. Korkeammat endostatiini- ja VEGF-C-pitoisuudet liittyivät matalampaan 
syntymäpainoon, sekä ennen syntymää toteutettuun kortisonihoitoon. Gestaatioiällä ei ollut 
yhteyttä imulimanäytteiden kasvutekijäpitoisuuksien kanssa. Kohdunsisäistä tulehdusta 
heijastavat kliiniset tekijät olivat yhteydessä matalampiin PlGF-, endostatiini- ja VEGF-C-
pitoisuuksiin. Sisäänhengitysilman korkeampi happiosapaine (FiO2) ensimmäisen elinviikon 
aikana liittyi korkeampiin imulimanäytteiden endostatiinipitoisuuksiin.  
Kolmannessa osa-analyysissa täysiaikaisilla vastasyntyneillä tavattiin korkeampia 
napaveren endostatiinipitoisuuksia kuin pikkukeskosilla. Keskosryhmässä korkeampi 
endostatiinipitoisuus oli suoraan yhteydessä BPD:an. Tämä yhteys säilyi merkitsevänä 
logistisessa regressioanalyysissa, jossa huomioitiin tulosta mahdollisesti sekoittavia 
kliinisiä tekijöitä, joiden tiedetään lisäävän BPD:n riskiä.  
PlGF:n, endostatiinin sekä VEGF-C:n tasainen esiintyminen keuhkokehityksen 
kaikissa vaiheissa sekä johdonmukainen esiintyminen pikkukeskosilla syntymän jälkeen 
imulimassa painottaa kasvutekijöiden merkitystä normaalissa keuhkokehityksessä. Tämä 
yhteys korostuu endostatiinin osalta, sillä endostatiinipitoisuus napaveressä oli korkeampi 
täysiaikaisilla vastasyntyneillä kuin pikkukeskosilla. VEGFR-2:n värjäytymismalli saattaa 
heijastaa erityyppisten endoteelisolujen erilaistumista kehityksen aikana. 
Imulimassa havaittiin kaikkien kasvutekijöiden osalta, että matalammat 
kasvutekijäpitoisuudet ovat yhteydessä kohdunsisäiseen tulehdukseen liittyviin kliinisiin 
tekijöihin. Kohdunsisäinen tulehdus saattaa näin ollen aiheuttaa verisuonikehityksen 
vähenemistä. Verisuonikehityksen hidastumiseen liittyen VEGFR-2:n värjäytymisen 
väheneminen keuhkorakkuloiden hiussuoniendoteelisoluissa BPD-ryhmässä sopii 
vaskulaariseen hypoteesiin, jonka mukaan BPD:n kehittymisen syynä on keuhkojen 
verisuonikehityksen pysähtyminen. Korkeampi FiO2-paine oli pikkukeskosilla yhteydessä 
imuliman ja napaveren korkeampaan endostatiinipitoisuuteen. Tämän lisäksi napaveren 
korkeampi endostatiinipitoisuus oli suoraan yhteydessä BPD:an. Nämä tulokset viittaavat 
siihen, että korkea endostatiinipitoisuus on haitallinen pikkukeskosen keuhkokehityksessä 
ja lisää pikkukeskosen riskiä sairastua BPD:n. 
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Sammandrag (Swedish summary) 
Framsteg inom vården av prematurt födda barn har möjliggjort överlevnaden av barn med 
en födelsevikt på 500-1000 g. I detta skede är lungorna inte fullt utvecklade, vilket utsätter 
barnet för kronisk lungskada, bronkopulmonär dysplasi (BPD). BPD utvecklas då 
utvecklingen av blodkärl i lungan störs till följd av en störning i balansen mellan 
tillväxtfaktorer som styr blodkärlens utveckling. Målsättningen för avhandlingen var att 
undersöka rollen av placental growth factor (PlGF), endostatin och vascular endothelial 
growth factor (VEGF) -C, samt deras receptorer VEGFR-2 och VEGFR-3 i 
människolungans fysiologiska utveckling och i utvecklingen av BPD. De undersökta 
tillväxtfaktorerna valdes på basen av deras samband med VEGF-A, som har en viktig 
blodkärlsstimulerande roll i lungans fysiologiska utveckling. Hos små prematurer finns ett 
samband mellan en lägre koncentration av VEGF-A och en högre risk för BPD. 
Avhandlingen består av tre delanalyser. I den första delanalysen färgades lungbiopsier 
immunohistokemiskt. Proverna samlades från avlidna patienter som vårdats på Barn- och 
ungdomssjukhuset i Helsingfors under åren 1991-2000. Lungbiopsier togs från foster 
(graviditetsvecka 16-20), små prematurer (graviditetsvecka 24-32) och fullgångna nyfödda 
(graviditetsvecka 38-42) utan lungskada, samt från små prematurer med akut (tidig 
respiratory distress syndrome (RDS), avliden vid ålder 0-2 dagar), subakut (sen RDS, avliden 
vid ålder 3-10 dagar) eller kronisk lungskada (BPD). Proven färgades med antikroppar för 
PlGF, endostatin, VEGF-C, VEGFR-2 samt VEGFR-3. Färgningsmönstret analyserades 
både inom och mellan de olika grupperna. I den andra delanalysen bestod patientmaterialet 
av 54-59 små prematurer, som vårdats på intensivvårdsavdelningen på Barn- och 
ungdomssjukhuset i Helsingfors under åren 1993-2002. Materialet valdes så att hälften 
senare insjuknade i BPD, medan hälften klarade sig utan BPD. Trakealaspirat samlades 
dagligen genom en standardiserad metod under de första fem veckorna efter födseln. PlGF-, 
endostatin- och VEGF-C-koncentrationer mättes med ELISA-analys. I den tredje 
delanalysen samlades navelblod från såväl fullgångna barn (n=48) som små prematurer 
(n=92) i samband med förlossningen. Endostatinkoncentrationer mättes med ELISA-analys 
och jämförelser gjordes både inom och mellan grupperna. 
Samtliga tillväxtfaktorer och receptorer kunde påvisas i de olika stadierna av 
lungans utveckling från och med gestationsåldern 16 veckor och framöver. Under tidigare 
utvecklingsstadier sågs positiv färgning i epitelceller (PlGF, endostatin, VEGF-C) och 
endotelceller (endostatin) i hela lungan. I senare utvecklingsstadier sågs färgning endast i 
epitelceller i övre delar av lungan (PlGF, VEGF-C). VEGFR-3 förekom i lymfatiska 
strukturer under alla stadier av lungans utveckling. VEGFR-2 förekom i tidigare skeden av 
utvecklingen både i lymfatiska och venösa endotelceller och senare i arteriella 
endotelceller. Alveolära makrofager färgades positivt för VEGF-C endast i grupperna för 
sen RDS och BPD. För endostatin fanns positivitet i alveolära epitelceller och makrofager i 
grupperna för sen RDS och BPD i ungefär hälften av fallen. I de övriga grupperna sågs 
ingen färgning. VEGFR-2-färgningen var relativt jämn mellan grupperna, med undantag av 
att färgning av kapillära endotelceller var nedsatt i BPD-gruppen. 
I trakealaspirat var PlGF-koncentrationen jämn, medan endostatin och VEGF-C-
koncentrationerna minskade under först veckan efter födseln. En högre endostatin- och 
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VEGF-C-koncentration korrelerade med en lägre födelsevikt, såväl som med 
administration av kortikosteroider före födseln. Ingen korrelation kunde påvisas mellan 
tillväxtfaktorerna och gestationsåldern. Kliniska parametrar som reflekterar inflammation 
före födseln korrelerade med lägre PlGF-, endostatin- och VEGF-C-koncentrationer i 
trakealaspirat. En högre koncentration av inandat syre under de första två veckorna efter 
födseln (FiO2) korrelerade med en högre endostatinkoncentration i trakealaspirat. 
I navelblod var endostatinkoncentrationen högre hos fullgångna än hos prematura 
barn. Bland prematurer hade en högre endostatinkoncentration samband med en högre risk 
för BPD. Associationen förblev signifikant efter logistisk regressionsanalys med 
korrigering för faktorer som hör ihop med en högre risk för BPD.  
Den jämna expressionen av PlGF, endostatin och VEGF-C i immunohistokemi samt 
i trakealaspirat stöder tanken om att alla undersökta tillväxtfaktorer spelar en roll i lungans 
fysiologiska utveckling. För endostatin stärks sambandet ytterligare genom att fullgångna 
nyfödda har högre endostatinkoncentrationer i navelblod än prematurer. VEGFR-2-
expressionsmönstret verkar avspegla den fortsatta differentieringen av endotelceller under 
fosterutvecklingen. 
En lägre koncentration av alla de undersökta tillväxtfaktorerna i trakealaspirat kunde 
associeras med kliniska parametrar för inflammation före födseln. Detta kan reflektera en 
dämpning av blodkärlsutveckling under inflammatoriska tillstånd. I BPD-gruppen var 
VEGFR-2-färgningen i kapillära endotelceller betydligt lägre än i de andra grupperna. 
Utvecklingen av BPD är associerad med nedsatt angiogenes, vilket VEGFR-2-färgningen i 
BPD-gruppen verkar återspegla. Högre FiO2 kunde associeras med en högre 
endostatinkoncentration både i trakealaspirat och i navelblod. En högre 
endostatinkoncentration i navelblod av prematurer kunde direkt associeras med 
utvecklingen av BPD och associationen förblev signifikant även efter logistisk 
regressionsanalys. Tillsammans tyder resultaten på att en högre endostatinkoncentration 
hos prematurer försämrar den fysiologiska lungutvecklingen och ökar risken för BPD. 
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